

A

Patent
238/298

08/12/99
Jc690 U.S. PTO

To: Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Jc135 U.S. PTO
09/31/99
08/12/99

NEW APPLICATION TRANSMITTAL
UTILITY

Sir:

Transmitted herewith for filing is a **utility** patent application:

Inventor(s): Peter B. Dervan, et al.

Title: INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY
MODIFIED POLYAMIDES

I. PAPERS ENCLOSED HEREWITH FOR FILING UNDER 37 CFR § 1.53(b):

39 Page(s) of Written Description
8 Page(s) Claims
1 Page(s) Abstract
19 Sheets of Drawings ☒ Informal ☐ Formal

II. ADDITIONAL PAPERS ENCLOSED IN CONNECTION WITH THIS FILING:

- ☒ Declaration
☒ Power of Attorney: ☐ Separate or ☒ Combined with Declaration
☒ Assignment to California Institute of Technology and assignment cover sheet
☒ **3** Verified Statement establishing "**Small Entity**" under 37 CFR §§ 1.9 and 1.27
☐ Priority Document No(s): _____

SD-126116.1(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EL088594244US
Express Mail Label No.

August 12, 1999
Date of Deposit

TAMARA TURNER
Name of Person Mailing Paper
Tamara Turner
Signature of Person Mailing Paper

- ☐ Information Disclosure Statement w/PTO 1449 ☐ Copy of Citations
- ☒ Preliminary Amendment
- ☒ Return Postcard

III. THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

BASIC FILING FEE:							\$760.00
Total Claims	26	-	20	=	6	x \$18.00	\$108.00
Independent Claims	8	-	3	=	5	x \$78.00	\$390.00
Multiple Dependent Claims	\$260	(if applicable)				<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS							\$1,258.00
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28. If applicable, Verified Statement must be attached.							<input checked="" type="checkbox"/> \$629.00
Misc. Filing Fees (Recordation of Assignment -- \$40)							\$40.00
TOTAL FEES SUBMITTED HEREWITH							\$669.00

IV. METHOD OF PAYMENT OF FEES

- ☒ A check in the amount of \$669.00.
- ☐ Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of _____.
- ☐ This application is being filed without fee or Declaration under 37 CFR § 1.53.

V. AUTHORIZATION to CHARGE FEES

The Commissioner is authorized to charge Lyon & Lyon's Deposit Account No. **12-2475** for the following:

- ☒ 37 CFR § 1.16(a), (f) or (g) – **(Filing fees)**
- ☒ 37 CFR § 1.16(b), (c) and (d) – **(Presentation of Extra Claims)**
- ☒ 37 CFR § 1.16(e) – **(Surcharge for filing the basic filing fee and/or Declaration on a date later than the filing date of the application)**
- ☒ 37 CFR § 1.17 – **(Any Application processing fees)**


☒ Credit Lyon & Lyon's Deposit Account No. **12-2475** for overpayment of fees.

Respectfully submitted,

LYON & LYON LLP

Dated: 08/12/99

By:



Daniel M. Chambers

Reg. No. 34,561

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(858) 552-8400

652420-4042E0

Applicant or Patentee: Peter B. Dervan and Eldon E. Baird
Serial or Patent No.: To Be Assigned
Filed or Issued: Herewith
For: INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY MODIFIED POLYAMIDES

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(e) and 1.27(d)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: CALIFORNIA INSTITUTE OF TECHNOLOGY
ADDRESS OF ORGANIZATION: 1200 East California Boulevard
Pasadena, California 91125

TYPE OF ORGANIZATION:

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE:)
(CITATION OF STATUTE:)
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3))
IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED
STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE:)
(CITATION OF STATUTE:)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, with regard to the invention entitled INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY MODIFIED POLYAMIDES by inventor(s) Peter B. Dervan and Eldon E. Baird described in

- ☒ the specification filed herewith.
☐ application serial no. _____, filed _____.
☐ patent no. _____, issued _____.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

**NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)*

NAME	GeneSoft, Inc.		
ADDRESS	Two Corporate Drive, South San Francisco, California 94080		
	<input type="checkbox"/> INDIVIDUAL	<input checked="" type="checkbox"/> SMALL BUSINESS CONCERN	<input type="checkbox"/> NONPROFIT ORGANIZATION
NAME	Prolinx, Inc.		
ADDRESS	22322 20 th Avenue S.E., Bothell, Washington 98021		
	<input type="checkbox"/> INDIVIDUAL	<input checked="" type="checkbox"/> SMALL BUSINESS CONCERN	<input type="checkbox"/> NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small

entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

Adam Cochran

TITLE OF PERSON IN ORGANIZATION:

The Intellectual Property Counsel

ADDRESS OF PERSON SIGNING:

CALIFORNIA INSTITUTE OF TECHNOLOGY

1200 E. California Blvd., Pasadena, CA 91125

Signature



Date

JUL 27 1999

Applicant or Patentee: Peter B. Dervan and Eldon E. Baird
 Serial or Patent No.: To Be Assigned
 Filed or Issued: Herewith
 For: INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY MODIFIED
 POLYAMIDES

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
 (37 CFR 1.9(d) and 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am:

 the owner of the small business concern identified below:
 X an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: PROLINX, INC.
 ADDRESS OF CONCERN: 22322 20th Avenue S.E.
 Bothell, Washington 98021

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY MODIFIED POLYAMIDES, by inventors Peter B. Dervan and Eldon E. Baird described in

 X the specification filed herewith.
 application serial number , filed .
 Patent No. , issued .

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

**NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)*

NAME: California Institute of Technology
 ADDRESS: 1200 East California Blvd., Pasadena, California 91125
[] INDIVIDUAL [] SMALL BUSINESS CONCERN [X] NONPROFIT ORGANIZATION


NAME: GeneSoft, Inc.
 ADDRESS: Two Corporate Drive, South San Francisco, California 94080
[] INDIVIDUAL [X] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: MARK L. STOLOWITZ
 TITLE OF PERSON IN ORGANIZATION: CHIEF TECHNOLOGY OFFICER
 ADDRESS OF PERSON SIGNING: 22322 20th Avenue S.E.
Bothell, Washington 98021

Signature



Date

7/27/99

Applicant or Patentee: Peter B. Dervan and Eldon E. Baird
 Serial or Patent No.: To Be Assigned
 Filed or Issued: Herewith
 For: INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY MODIFIED POLYAMIDES

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(d) and 1.27(c)) - SMALL BUSINESS CONCERN

I hereby declare that I am:

 the owner of the small business concern identified below:
 X an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: GENESOFT, INC.
 ADDRESS OF CONCERN: Two Corporate Drive
 South San Francisco, California 94080

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY MODIFIED POLYAMIDES, by inventors Peter B. Dervan and Eldon E. Baird described in

 X the specification filed herewith.
 application serial number , filed .
 Patent No. , issued .

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

**NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)*

NAME: California Institute of Technology
 ADDRESS: 1200 East California Blvd., Pasadena, California 91125
[] INDIVIDUAL [] SMALL BUSINESS CONCERN [X] NONPROFIT ORGANIZATION


NAME: Prolinx, Inc.
 ADDRESS: 22322 20th Avenue S.E., Bothell, Washington 98021
[] INDIVIDUAL [X] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: David B. Singer
 TITLE OF PERSON IN ORGANIZATION: President & CEO
 ADDRESS OF PERSON SIGNING: Two Corporate Drive
South San Francisco, CA 94080

Signature



Date

August 6, 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Peter B. Dervan et al.

Serial No.: To be assigned

Filed: August 11, 1999

For: INHIBITION OF MAJOR GROOVE
DNA BINDING PROTEINS BY MODIFIED
POLYAMIDES

)
) **Group Art Unit:** ArtUnit

)
) **Examiner:** Examiner

PRELIMINARY AMENDMENT

Box New Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Please amend the application as follows:

In the Specification:

On page 1, line 7, please insert after "This application": --claims priority to
PCT/US98/02684 filed February 13, 1998, and--

Respectfully submitted,

LYON & LYON LLP

By: 

Daniel M. Chambers

Reg. No. 34,561

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(858) 552-8400

APPLICATION

FOR

UNITED STATES LETTERS PATENT

TO THE ASSISTANT COMMISSIONER OF PATENTS:

BE IT KNOWN THAT WE PETER B. DERVAN AND ELDON J. BAIRD

have invented certain new and useful improvements in

**“INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY MODIFIED
POLYAMIDES”**

of which the following is a specification:

Inhibition of Major Groove DNA Binding Proteins By Modified Polyamides

The U.S. Government has certain rights to this invention pursuant to Grant Nos. GM 26453, 27681, and 47530 awarded by the National Institute of Health.

5

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of PCT/US97/03332 filed February 20, 1997, Serial No. 08/853,522 filed May 8, 1997 and PCT/US97/12722 filed July 21, 1997 which are continuation-in-part applications of Serial No. 08/837,524 filed April 21, 1997 and Serial No. 08/607,078 filed February 26, 1996; provisional application 60/042,022, filed April 16, 1997; provisional application 60/043,444 filed April 8, 1997; PCT/US98/[MBHB 97,853] filed January 21, 1998; PCT/US98/[MBHB 97,854] filed January 29, 1998; and, PCT/US98/[MBHB98,016], filed January 29, 1998. The specifications of these applications are incorporated herein by reference.

15

BACKGROUND OF THE INVENTION

Field of the Invention

This invention relates to polyamides which bind to pre-determined sites of the minor groove of double-stranded DNA and have an α -amino acid domain ("positive patch") capable of inhibiting the activity of major groove DNA-binding proteins.

Background of the Invention

Polyamides containing *N*-methylpyrrole (Py) and *N*-methylimidazole (Im) amino acids bind to predetermined sequences in the minor groove of DNA with affinities and specificities comparable to naturally occurring DNA binding proteins (Trauger, et al. (1996) *Nature* 382, 559-561; Swalley, et al. (1997) *J. Am. Chem. Soc.* 119, 6953-6961; Turner, et al. (1997) *J. Am. Chem. Soc.* 119, 7636-7644). Sequence specificity is determined by a code of oriented side-by-side pairings of the Py and Im amino (Wade, et al. (1992) *J. Am. Chem. Soc.* 114, 8783-8794; Mrksich, et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89, 7586-7590; Wade, et al. (1993) *Biochemistry* 32, 11385-11389; Mrksich,

- et al. (1993) *J. Am. Chem. Soc.* 115, 2572-2576; White, et al. (1997) *Chem. Biol.* 4, 569-578; White, et al. (1997) *J. Am. Chem. Soc.* 119, 8756-8765). An Im/Py pairing targets a G•C base pair, while Py/Im pair recognizes C•G. The Py/Py pair is degenerate and targets both A•T and T•A base pairs (Pelton, et al. (1989) *Proc. Natl. Acad. Sci. USA* 86, 5723-5727; Chen, et al. (1994) *Nature Struct. Biol.* 1, 169-175; White, et al. (1996) *Biochemistry* 35, 12532-12537). The validity of the pairing rules for ligand design is supported by a variety of polyamide structural motifs which have been characterized by footprinting, affinity cleaving, 2-D NMR, and x-ray methods. The Py/Py pair is degenerate and targets both A•T and T•A base pairs. Polyamides have been found to be cell permeable and to inhibit transcription factor binding and expression of a designated gene (Gottesfeld, et al. (1997) *Nature* 387, 202-205; Nealy, et al. (1997) *J. Mol. Biol.* in press). Py/Im polyamides offer a potentially general approach for gene regulation, provided that efficient inhibition of DNA-binding can be achieved for a variety of transcription factors.
- 15 Several approaches for the development of synthetic ligands which interfere with protein-DNA recognition have been reported. Oligodeoxyribonucleotides which recognize the major groove of double-helical DNA via triple-helix formation bind to a broad range of sequences with high affinity and specificity (Moser, et al. (1987) *Science* 238, 645-650; Thuong, et al. (1993) *Angew. Chem. Int. Ed. Engl.* 32, 666-690). Although
- 20 oligonucleotides and their analogs have been shown to disrupt protein-DNA binding (Maher, et al. (1992) *Biochemistry* 31, 70-81; Duval-Valentin, et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89, 504-508; Nielsen, P. E. (1997) *Chem. Eur. J.* 3, 505-508), the triple-helix approach is limited to purine tracts and suffers from poor cellular uptake. There are a few examples of carbohydrate-based ligands which interfere with protein-DNA
- 25 recognition, but oligosaccharides cannot currently recognize a broad range of DNA sequences (Ho, et al. (1994) *Proc. Natl. Acad. Sci. USA* 91, 9203-9207; Liu, et al. (1996) *Proc. Natl. Acad. Sci. USA* 93, 940-944). Analogs of distamycin (PyPyPy) appended with multiple cationic substituents have been found to inhibit protein binding. Rational

design of tripyrrole peptides that complex with DNA by both selective minor-groove binding and electrostatic interaction with the phosphate backbone. (Bruice (1992) *Proc. Natl. Acad. Sci. USA* 89, 1700-1704; Chiang, et al. (1997) *Proc. Natl. Acad. Sci. USA* 94, 2811-2816; Bruice, et al. (1997) *Bioorg. Med. Chem.* 5, 685-692). Based on these
 5 encouraging results, we wished to identify similar charged residues which could be appended to a Py/Im polyamide via linear solid phase synthesis and would not compromise polyamide binding specificity.

Proteins use a diverse structural library to recognize their target sequences (Steitz, T. A. (1990) *Quart. Rev. Biophys.* 23, 205-280). Proteins such as TBP bind exclusively
 10 in the minor groove (Kim, et al. (1993) *Nature* 365, 512-520), others, such as GCN4 Oakley, M. G. & Dervan, P. B. (1990) Structural motif of the GCN4 DNA binding domain characterized by affinity cleaving (Oakley, et al. (1990) *Science* 248, 847-850; Ellenberger, et al. (1992) *Cell* 71, 1223-1237; König, et al. (1993) *J. Mol. Biol.* 233, 139-154), bind exclusively in the major groove, and certain proteins such as Hin recombinase
 15 recognize both grooves (Sluka, et al. (1990) *Biochemistry* 29, 6551-6561; Feng, et al. (1994) *Science* 263, 348-355). Polyamides have been found to interfere with protein-DNA recognition in cases where contacts in the minor groove are important for protein-DNA binding affinity. For example, within the nine zinc-finger protein TFIIIA, fingers 4 and 6 bind in or across the minor groove and are required for high affinity binding ($K_a = 5 \times 10^9 \text{ M}^{-1}$).
 20 An eight-ring hairpin polyamide ($K_a = 3 \times 10^{10} \text{ M}^{-1}$) targeted to the minor groove contact region of finger 4 has been recently found to efficiently inhibit protein binding.

X-Ray crystallography studies reveal that DNA bound by a 4-ring homodimeric polyamide is unaltered from its natural B-form structure, with all polyamide/DNA
 25 contacts confined to the minor groove (Kielkopf, et al. *Nature Struct. Biol.*, in press). Polyamides have been shown to bind simultaneously with ligands that exclusively occupy the major groove (Oakley, et al. (1992). *Biochemistry* 31, 10969-10975; Park, et al. (1992) *Proc. Natl. Acad. Sci. USA* 89, 6653-6657). For example, an 8-ring hairpin

polyamide and a recombinant protein containing only the three amino-terminal zinc fingers of TFIIIA which are in the major groove were found to co-occupy the TFIIIA binding site. Similarly, the three-ring homodimer ImPyPy bound simultaneously with the bZIP protein GCN4 (226-281).

5 Intrinsic DNA curvature and protein induced DNA bending are also involved in the regulation of gene transcription, replication initiation, and other processes (Perez-Martin, J., et al. (1994) *Microbiological Reviews* 58, 268-290; Polaczek, et al. (1997), submitted). DNA is an inherently flexible polymer and neutral backbone analogs of DNA curve, where rigidity is maintained in natural DNA by coulombic repulsion
10 between phosphates on the same strand Strauss, et al. (1994) *Science* 266, 1829-1834; Manning, G. S. (1983) *Biopolymers* 22, 689-729). Sequence-dependent curvature of DNA is caused both by differential solvation in the minor groove and differential base stacking leading to alteration of roll and tilt values (Dlakic, et a. (1996) *J. Biological Chemistry* 271, 17911-17919; Bolshoy, et al. (1991) *Proc. Natl. Acad. Sci., USA* 88,
15 2312-2316).

 Proteins and other ligands that bend DNA alter the stacking of the bases by intercalation of hydrophobic groups, alter the effective Debye length of the surface through charge screening, or bend through energetic compensation for tight binding events. An example of a protein that seems to work through all three mechanisms in
20 bending DNA >160 degrees is integration host factor (IHF) (Rice, et al. (1996) *Cell* 87,1295-1306). Previously, it has been shown that artificial sequence specific DNA bending ligands can be designed that utilize bidentate tight binding third strand oligonucleotides to constrict the intervening duplex and bend DNA (Liberles, et al. (1996) *Proc. Natl. Acad. Sci., USA* 93, 9510-4; Akiyama, et al. (1996) *Proc. Natl.*
25 *Acad. Sci., USA* 93, 12122-12127; Akiyama, et al. (1996) *J. Biological Chemistry* 271, 29126-29135; Akiyama, et al. (1997) *Biochemistry* 36, 2307-2315).

Compounds that bind in the minor groove such as distamycin and DAPI have been shown to alter DNA rigidity (Larsson, et al. (1996) *J. Physical Chemistry* 100, 3252-3263; McCarthy, et al. (1991) *Nucleic Acids Research* 19, 3421-9; Barcelo, et al. (1991) *Biochemistry* 30, 4863-73.). While such compounds form few specific contacts and binding is dominated by the positive charge, polyamide analogs of distamycin have been designed that form specific high affinity structures with DNA in the minor groove. In such compounds, sequence specificity is determined by the sequence of side-by-side amino acid pairings, where imidazole (Im) opposite pyrrole (Py) recognizes a GC base pair, Py-Im recognizes CG, Py-Py is degenerate for AT or TA, while Im-Im pairing is disfavored (Wade, et al. (1992) *J. Am. Chem. Soc.* 114, 87838794; Mrksich, et al. (1992) *Proc. Natl. Acad. Sci., USA* 89,7586-7590; Wade, et al. (1993) *Biochemistry* 32, 1138511389; Pelton, et al. (1989) *Proc. Natl. Acad. Sci., USA* 86, 57235727; Pelton, et al. (1990) *J. Am. Chem. Soc.* 112,1393-1399). This recognition motif generality has been demonstrated for a large number of sequences and is directly supported by NMR data (Mrksich, et al. (1993) *J. Am. Chem. Soc.* 115, 2572-2576; Geierstanger, et al. (1994) *Biochemistry* 33, 3055-3062; Geierstanger, et al. (1993) *J. Am. Chem. Soc.* 115,4474-4482; Geierstanger, et al. (1994) *Science* 266, 646-650; Mrksich, et al. (1995) *J. Am. Chem. Soc.* 117,3325-3332; Mrksich, et al. (1993) *J. Am. Chem. Soc.* 115, 9892-9899; Dwyer, et al. (1993) *J. Am. Chem. Soc.* 115, 9900-9906; Mrksich, et al. (1994) *J. Am. Chem. Soc.* 116, 3663-3664; Mrksich, et al. (1994) *J. Am. Chem. Soc.* 116, 79837988; Chen, et al. (1994) *J. Am. Chem. Soc.* 116, 6995-7005; Cho, et al. (1995) *Proc. Natl. Acad. Sci., USA* 92, 10389-10392).

BRIEF DESCRIPTION OF THE FIGURES

- FIGURE 1. Schematic models of polyamides targeted to GCN4 binding site.
 FIGURE 2. Schematic models of Arg-Pro-Arg polyamides.
 FIGURE 3. Structure of DNA binding domain of Hin recombinase.

- FIGURE 4. Eight-ring hairpin polyamides.
- FIGURE 5. Synthesis of Arg-Pro-Arg polyamides.
- FIGURE 6. GCN4 gel mobility shift experiments.
- FIGURE 7. Arg-Pro-Arg-Arg-Arg-Arg polyamides.
- 5 FIGURE 8. GCN4 gel mobility shift experiments.
- FIGURE 9. Aliphatic amino acid substitutions in positive patch domain.
- FIGURE 10. Structure of ImPyPyPy- γ -PyPyPyPy-C7-RPR.
- FIGURE 11. Quantitative Dnase footprint experiments.
- FIGURE 12. Structural requirements for GCN4 binding.
- 10 FIGURE 13. Binding domains and chemical structures of PA1 and PA2.
- FIGURE 14. Gel shift analysis of oligonucleotides 2-6, 9 on a 3' 32 P end-labeled restriction fragment.
- FIGURE 15. Gel shift analysis of oligonucleotides 2 (A) and 9 (B) on a 3' 32 P end-labeled restriction fragment.
- 15 FIGURE 16. Gel shift analysis of oligonucleotide 2 on a 3' 32 P end-labeled restriction fragment generated with *EcoRI* and *HindIII*.
- FIGURE 17. Gel shift analysis of oligonucleotide 2 on a 3' 32 P end-labeled restriction fragment generated with *EcoRI* and *HindIII*.
- FIGURE 18. MPE and DNase I footprinting analysis of oligonucleotide 2 on a 3' 32 P end-labeled restriction fragment generated with *EcoRI* and *PvuII*.
- 20

SUMMARY OF THE INVENTION

This invention provides improved polyamides comprising a positive patch that, upon binding of the polyamide to the minor groove of a DNA molecule, is able to contact

25 nucleotides in the major groove of a DNA molecule. The positive patch may comprise any chemical moiety that delivers a charge to the DNA molecule. The invention further comprises polyamides comprising having the ability to alter the conformation of a DNA molecule such that the function of a conformation-dependent DNA binding protein is inhibited. As such, the polyamides inhibit gene expression by binding the minor groove

30 DNA sequence and displacing or preventing the binding or function of DNA-binding proteins such as transcription factors.

DETAILED DESCRIPTION

Within this application, unless otherwise stated, definitions of the terms and illustration of the techniques of this application may be found in any of several well-

5 known references such as: Sambrook, J., *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1989); Goeddel, D., *ed.*, *Gene Expression Technology, Methods in Enzymology*, Vol. 185, Academic Press, San Diego, CA (1991); "Guide to Protein Purification" in Deutscher, M.P., *ed.*, *Methods in Enzymology*, Academic Press, San Diego, CA (1989); Innis, *et al.*, *PCR Protocols: A Guide to Methods*
10 *and Applications*, Academic Press, San Diego, CA (1990); Freshney, R.I., *Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed.*, Alan Liss, Inc. New York, NY (1987); Murray, E.J., *ed.*, *Gene Transfer and Expression Protocols*, pp. 109-128, The Humana Press Inc., Clifton, NJ and Lewin, B., *Genes VI*, Oxford University Press, New York (1997).

15 For the purposes of this application, a *promoter* is a regulatory sequence of DNA that is involved in the binding of RNA polymerase to initiate transcription of a gene. A *gene* is a segment of DNA involved in producing a peptide, polypeptide or protein, including the coding region, non-coding regions preceding ("leader") and following ("trailer") the coding region, as well as intervening non-coding sequences ("introns")
20 between individual coding segments ("exons"). Coding refers to the representation of amino acids, start and stop signals in a three base "triplet" code. Promoters are often upstream ("5' to") the transcription initiation site of the corresponding gene. Other regulatory sequences of DNA in addition to promoters are known, including sequences involved with the binding of transcription factors, including response elements that are
25 the DNA sequences bound by inducible factors. Enhancers comprise yet another group of regulatory sequences of DNA that can increase the utilization of promoters, and can function in either orientation (5'-3' or 3'-5') and in any location (upstream or downstream) relative to the promoter. Preferably, the regulatory sequence has a positive activity, i.e., binding of an endogeneous ligand (e.g. a transcription factor) to the
30 regulatory sequence increases transcription, thereby resulting in increased expression of

the corresponding target gene. In such a case, interference with transcription by binding a polyamide to a regulatory sequence would reduce or abolish expression of a gene.

The promoter may also include or be adjacent to a regulatory sequence known in the art as a *silencer*. A silencer sequence generally has a negative regulatory effect on expression of the gene. In such a case, expression of a gene may be increased directly by using a polyamide to prevent binding of a factor to a silencer regulatory sequence or indirectly, by using a polyamide to block transcription of a factor to a silencer regulatory sequence.

It is to be understood that the polyamides of this invention bind to double stranded DNA in a sequence specific manner. The function of a segment of DNA of a given sequence, such as 5'-TATAAA-3', depends on its position relative to other functional regions in the DNA sequence. In this case, if the sequence 5'-TATAAA-3' on the sense strand of DNA is positioned about 30 base pairs upstream of the transcription start site, the sequence forms part of the promoter region (Lewin, *Genes VI*, pp. 831-835). On the other hand, if the sequence 5'-TATAAA-3' is downstream of the transcription start site in a coding region and in proper register with the reading frame, the sequence encodes the tyrosyl and lysyl amino acid residues (Lewin, *Genes VI*, pp. 213-215).

While not being held to one hypothesis, it is believed that the binding of the polyamides of this invention modulate gene expression by altering the binding of DNA binding proteins, such as RNA polymerase, transcription factors, TBF, TFIIB and other proteins. The effect on gene expression of polyamide binding to a segment of double stranded DNA is believed to be related to the function, e.g., promoter, of that segment of DNA.

It is to be understood by one skilled in the art that the improved polyamides of the present invention may bind to any of the above-described DNA sequences or any other sequence having a desired effect upon expression of a gene. In addition, U.S. Patent No. 5,578,444 describes numerous promoter targeting sequences from which base pair sequences for targeting an improved polyamide of the present invention may be identified.

It is generally understood by those skilled in the art that the basic structure of DNA in a living cell includes both *major* and a *minor groove*. For the purposes of

describing the present invention, the *minor groove* is the narrow groove of DNA and the *major groove* is the deep groove of DNA as illustrated in common molecular biology references such as Lewin, B., *Genes VI*, Oxford University Press, New York (1997).

It is further understood by those skilled in the art that a DNA binding protein is a protein capable of making contact with a DNA molecule, generally in the major groove, through hydrogen bonds, ionic bonds and/or hydrophobic interactions as illustrated in common molecular biology references such as Lewin, *supra*, or Alberts, et al., Eds., *Molecular Biology of the Cell*, 3rd, Ed., Garland Publishing, Inc., New York, 1994. Preferably, a DNA-binding protein is one that affects gene expression following binding to a DNA molecule.

Several basic motifs of DNA-binding proteins are known to those skilled in the art. One such conformation is the *helix-turn-helix* motif, which includes a specific subclass known as *homeodomain proteins*. Other common motifs include the *zinc finger* motif, the *leucine zipper* motif, and the *helix-loop-helix* motif. A DNA-binding protein of this application may maintain any of the above-described motifs or any other motif that provides a protein with the ability to bind DNA and affect gene expression.

To affect gene expression in a cell, which may include causing an increase or a decrease in gene expression, a effective quantity of one or more polyamide is contacted with the cell and internalized by the cell. The cell may be contacted *in vivo* or *in vitro*. Effective extracellular concentrations of polyamides that can modulate gene expression range from about 10 nanomolar to about 1 micromolar. Gottesfeld, J.M., et al., *Nature* 387 202-205 (1997). To determine effective amounts and concentrations of polyamides *in vitro*, a suitable number of cells is plated on tissue culture plates and various quantities of one or more polyamide are added to separate wells. Gene expression following exposure to a polyamide can be monitored in the cells or medium by detecting the amount of the protein gene product present as determined by various techniques utilizing specific antibodies, including ELISA and western blot. Alternatively, gene expression following exposure to a polyamide can be monitored by detecting the amount of messenger RNA present as determined by various techniques, including northern blot and RT-PCR.

Similarly, to determine effective amounts and concentrations of polyamides for *in vivo* administration, a sample of body tissue or fluid, such as plasma, blood, urine,

cerebrospinal fluid, saliva, or biopsy of skin, muscle, liver, brain or other appropriate tissue source is analyzed. Gene expression following exposure to a polyamide can be monitored by detecting the amount of the protein gene product present as determined by various techniques utilizing specific antibodies, including ELISA and western blot.

5 Alternatively, gene expression following exposure to a polyamide can be monitored by detecting the amount of messenger RNA present as determined by various techniques, including northern blot and RT-PCR.

The polyamides of this invention may be formulated into diagnostic and therapeutic compositions for *in vivo* or *in vitro* use. Representative methods of

10 formulation may be found in *Remington: The Science and Practice of Pharmacy*, 19th ed., Mack Publishing Co., Easton, PA (1995).

For *in vivo* use, the polyamides may be incorporated into a physiologically acceptable pharmaceutical composition that is administered to a patient in need of treatment or an animal for medical or research purposes. The polyamide composition

15 comprises pharmaceutically acceptable carriers, excipients, adjuvants, stabilizers, and vehicles. The composition may be in solid, liquid, gel, or aerosol form. The polyamide composition of the present invention may be administered in various dosage forms orally, parentally, by inhalation spray, rectally, or topically. The term parenteral as used herein includes, subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or

20 intraperitoneally.

The selection of the precise concentration, composition, and delivery regimen is influenced by, *inter alia*, the specific pharmacological properties of the particular selected compound, the intended use, the nature and severity of the condition being treated or diagnosed, the age, weight, gender, physical condition and mental acuity of the intended

25 recipient as well as the route of administration. Such considerations are within the purview of the skilled artisan. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods.

Polyamides of the present invention are also useful for detecting the presence of double stranded DNA of a specific sequence for diagnostic or preparative purposes. The

30 sample containing the double stranded DNA can be contacted by polyamide linked to a solid substrate, thereby isolating DNA comprising a desired sequence. Alternatively,

polyamides linked to a suitable detectable marker, such as biotin, a hapten, a radioisotope or a dye molecule, can be contacted by a sample containing double stranded DNA.

The design of bifunctional sequence specific DNA binding molecules requires the integration of two separate entities: recognition and functional activity. Polyamides that specifically bind with subnanomolar affinity to the minor groove of a predetermined sequence of double stranded DNA are linked to a functional molecule, providing the corresponding bifunctional conjugates useful in molecular biology, genomic sequencing, and human medicine. Polyamides of this invention can be conjugated to a variety of functional molecules, which can be independently chosen from but is not limited to arylboronic acids, biotins, polyhistidines comprised from about 2 to 8 amino acids, haptens to which an antibody binds, solid phase supports, oligodeoxynucleotides, N-ethylnitrosourea, fluorescein, bromoacetamide, iodoacetamide, DL- α -lipoic acid, acridine, captothesin, pyrene, mitomycin, texas red, anthracene, anthrnilic acid, avidin, DAPI, isosulfan blue, malachite green, psoralen, ethyl red, 4-(psoraen-8-yloxy)-butyrate, tartaric acid, (+)- α -tocopheral, EDTA, methidium, acridine, Ni(II)•Gly-Gly-His, thiazole orange (TO), Dansyl, pyrene, N-bromoacetamide, and gold particles. Such bifunctional polyamides are useful for DNA affinity capture, covalent DNA modification, oxidative DNA cleavage, DNA photocleavage. Such bifunctional polyamides are useful for DNA detection by providing a polyamide linked to a detectable label. Detailed instructions for synthesis of such bifunctional polyamides can be found in copending U.S. provisional application 60/043,444, the teachings of which are incorporated by reference.

DNA complexed to a labeled polyamide can then be determined using the appropriate detection system as is well known to one skilled in the art. For example, DNA associated with a polyamide linked to biotin can be detected by a streptavidin / alkaline phosphatase system.

The present invention also describes a diagnostic system, preferably in kit form, for assaying for the presence of the double stranded DNA sequence bound by the polyamide of this invention in a body sample, such brain tissue, cell suspensions or tissue sections, or body fluid samples such as CSF, blood, plasma or serum, where it is desirable to detect the presence, and preferably the amount, of the double stranded DNA sequence

bound by the polyamide in the sample according to the diagnostic methods described herein.

The diagnostic system includes, in an amount sufficient to perform at least one assay, a specific polyamide as a separately packaged reagent. Instructions for use of the packaged reagent(s) are also typically included. As used herein, the term "package" refers to a solid matrix or material such as glass, plastic (e.g., polyethylene, polypropylene or polycarbonate), paper, foil and the like capable of holding within fixed limits a polyamide of the present invention. Thus, for example, a package can be a glass vial used to contain milligram quantities of a contemplated polyamide or it can be a microtiter plate well to which microgram quantities of a contemplated polyamide have been operatively affixed, i.e., linked so as to be capable of being bound by the target DNA sequence. "Instructions for use" typically include a tangible expression describing the reagent concentration or at least one assay method parameter such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent or sample admixtures, temperature, buffer conditions and the like. A diagnostic system of the present invention preferably also includes a detectable label and a detecting or indicating means capable of signaling the binding of the contemplated polyamide of the present invention to the target DNA sequence. As noted above, numerous detectable labels, such as biotin, and detecting or indicating means, such as enzyme-linked (direct or indirect) streptavidin, are well known in the art.

Trauger, et al. (*Nature*, 382: 559-561) and Swalley, et al. (*J. Am. Chem. Soc.* 119: 6953-6961) have described recognition of DNA by certain polyamides at subnanomolar concentrations. Pairing specific carboxamide groups allows for recognition of specific DNA sequences (Swalley, et al. *supra*). Polyamides comprising Hp, Im, and Py provide for coded targeting of pre-determined DNA sequences with high affinity and specificity. Hp, Im, and Py polyamides may be combined to form Im/Py, Py/Im, Hp/Py, and Py/Hp binding pairs which complement the four Watson-Crick base pairs A, C, G, and T. Table 1 illustrates such pairings.

TABLE 1*Pairing Codes for Base Pair Recognition**

Pair	G•C	C•G	T•A	A•T
Im/Py	+	-	-	-
Py/Im	-	+	-	-
Hp/Py	-	-	+	-
Py/Hp	-	-	-	+

*favored (+), disfavored (-)

5 Three-, four-, five- or six-ring improved polyamides of the present invention are covalently coupled to form six-, eight-, ten- or twelve-ring structures, respectively, that bind specifically to four or six base pair targets, respectively, at subnanomolar concentrations. As such, the improved polyamides of the present invention may be directed to any DNA sequence comprised of A, C, G, or T.

10 The instant invention provides polyamides having the ability to interfere with gene expression by altering the topology of a DNA molecule physically or by altering the chemical environment of the DNA molecule. By altering the topology of a DNA molecule, it is possible to inhibit the function of DNA-binding proteins that are dependent on DNA conformation for binding. The inclusion of a positive patch in a
 15 polyamide allows for alteration of the chemical environment surrounding the DNA molecule and serves to inhibit binding or function of DNA-binding proteins that bind the major groove of a DNA molecule.

Transcription and replication of DNA is dependent upon intrinsic DNA curvature and protein-induced DNA bending. Previously, sequence-specific DNA bending ligands
 20 have been designed to bind two noncontiguous target sites in the major groove and induce a bend in the DNA (Liberles, D. A. & Dervan, P. B. (1996) *Proc. Natl. Acad. Sci., USA* 93, 9510-4). This bend was shown to be dependent upon the linker length connecting the two sites. The present invention comprises sequence-specific polyamides targeted to the minor groove of the double helical linker region not overlapping either
 25 triple helical region, are capable of inhibiting bidentate third strand oligonucleotide binding. This inhibition through rigidification of the duplex is dependent upon the bend

angle of the DNA, but is independent of the order of addition of bending and straightening ligands. As such, polyamides may be useful for displacing DNA bending transcription factors in cells.

It has been demonstrated that artificial sequence-specific DNA bending ligands can be designed that utilize bidentate tight binding third strand oligonucleotides to constrict the intervening duplex and bend DNA (Liberles, et al. (1996) *Proc. Natl. Acad. Sci., USA* 93, 9510-4; Akiyama, et al. (1996) *Proc. Natl. Acad. Sci., USA* 93, 12122-12127; Akiyama, et al. (1996) *J. Biological Chemistry* 271, 29126-29135; Akiyama, et al. (1997) *Biochemistry* 36, 2307-2315). Presented herein is a mechanism of action by which certain improved polyamides affect DNA conformation, thus inhibiting the function of DNA-binding proteins that are dependent upon the conformation of DNA for binding. While compounds such as DAPI form a few specific contacts and binding is dominated by the positive charge of the compound, polyamide analogs of distamycin have been designed that form specific high affinity structures with DNA in the minor groove. Provided herein are polyamides having the ability to displace a DNA bending by rigidification of a bent region not contacted by the ligand. A polyamide of the present invention may be utilized to "straighten", defined herein as altering the conformation of a DNA molecule such that a conformationally-dependent DNA-binding protein is unable to bind to the DNA or function properly, DNA molecules of widely varying sequence.





The negatively charged DNA phosphate backbone provides a target for ligands designed to disrupt the unique microenvironment representing a protein binding site on the DNA double helix. The present invention comprises improved polyamides having a positive patch. Preferably, the positive patch contacts the phosphate backbone and disrupts the microenvironment, thereby preventing the binding and/or function of proteins that bind the DNA major groove. Polyamides that deliver a positive patch to the DNA backbone most likely destabilize the contacts between the protein side chains and the phosphate residues, and thereby inhibit protein binding (Bruce, et al. (1992). *Proc. Natl. Acad. Sci. USA* 89, 1700-1704; Chiang, et al. (1997). *Proc. Natl. Acad. Sci. USA* 94, 2811-2816; Bruce, et al. (1997). *Bioorg. Med. Chem.* 5, 685-692) (Figure 1).

The positive patch comprises any chemical moiety that is capable of delivering a charge to the chemical environment of the DNA molecule. The positive patch comprises

a charged group placed on the C-terminus, N-terminus, N-methyl group or other modifiable position of the polyamide. Preferably, the charged group comprises any amino acid having a net charge of at least +1. More preferably, the charged group is a primary, secondary, tertiary, quaternary amino group or a guanidinium or amidinium group. In one embodiment, the positive patch comprises an amino acid residue having a net positive charge joined to the C-terminus of a polyamide such that the polyamide has the ability to displace or prevent the binding of a DNA-binding protein to the major groove of a DNA molecule (Figure 12).



It has been demonstrated that a variety of polyamide motifs co-occupy the DNA helix at sites both overlapping and adjacent to certain DNA-binding proteins, such as GCN4 (Figure 1). Table 2 shows schematic models of polyamides targeted to the binding site of the bZIP transcriptional activator, GCN4: ImPyPy-Dp, ImPyPy- γ -ImPyPy- β -Dp, ImPyPyPy- γ -PyPyPyPy- β -Dp, and ImPyPy- γ -ImPyPy- β -PyPyPy-G-Dp. The nine-base pair (5'-CTGACTAAT-3') GCN4 binding site is indicated by brackets above and below the base pairs. Filled and unfilled circles represent imidazole (Im) and pyrrole (Py) polyamide rings, respectively. Diamonds and triangles represent β -alanine (β) and glycine (G), respectively. γ -Aminobutyric acid (γ) and dimethylaminopropylamide (Dp) are depicted as a curved line and a plus sign, respectively. Polyamide binding sites are shown in bold. Equilibrium association constants (K_a) for each polyamide binding to the indicated match site are shown at the right. Association constants were determined by DNase I footprinting; simultaneous binding was determined by gel mobility shift assay.

Table 2
Polyamide Motifs That Bind Simultaneously with Major Groove DNA-Binding
Proteins


Polyamide	Complex	K_a (M^{-1})
ImPyPy-Dp	5'-T G C C T G A C T A A T A G T -3'  3'-A C G G A C T G A T T A T C A -5'	1×10^5
ImPyPy-γ-ImPyPy-β-Dp	5'-T G C C T G A C T A A T A G T -3'  3'-A C G G A C T G A T T A T C A -5'	1×10^7
ImPyPyPy-γ-PyPyPyPy-β-Dp	5'-G C T G A C T A A T T T G T T A T C-3'  3'-C G A C T G A T T A A C A A T A G-5'	1×10^9
ImPyPy-γ-ImPyPy-β-PyPyPy-G-Dp	5'-T G C C T G A C T A A T A G T -3'  3'-A C G G A C T G A T T A T C A -5'	1×10^{10}

The improved polyamides of the present invention have at least three consecutive carboxamide pairings for binding DNA in the minor groove of a regulatory sequence of a duplex gene sequence, and a positive patch sequence for interference with DNA-binding protein function. The improved polyamides may further comprise a chiral hairpin turn having a stereochemical center substituted at the γ-position of the chiral hairpin turn of the molecule with the R-enantiomer of 2,4-diaminobutyric acid ($H_2NHCHCH_2CHNH_2-COOH$; "(R)^{H₂N} γ").


The present invention comprises improved polyamides having three or four-ring polyamide structures covalently coupled to form six-, eight-, ten- or twelve-ring hairpin structures, respectively, of the general structures I-VIII:




5




V



VI



VII



VIII

where X_{1-12} and X'_{1-12} are independently an imidazole such as N-methylimidazole (Im), a pyrrole such as N-methylpyrrole (Py), or a hydroxypyrrole such as 3-hydroxy-N-methylpyrrole (Hp). In addition, an improved polyamide of the present invention may further include a aliphatic amino acid such as β -alanine residue (β), an amide group such as dimethylaminopropylamide (Dp), an alcohol such as EtOH, an acid such as EDTA, or any derivative thereof may be joined to the β residue.

10

"A" represents a positive patch which comprises any chemical moiety that is capable of delivering a positive charge to the major groove of a DNA molecule. Preferably, the positive patch comprises a rigid group joined to a positively charged group. The rigid group positions the positively charged group such that contact with the major groove or the phosphate backbone of a DNA molecule is accomplished.

15

Preferably, the rigid group comprises one to ten amino acids. More preferably, the rigid group comprises one to eight amino acids. More preferably, the rigid group

20

comprises one to six amino acids. More preferably, the rigid group comprises one to four amino acids. Most preferably, the rigid group comprises two amino acids. Of the most preferred rigid group, the first amino acid is positioned adjacent to the polyamide and may comprise arginine, proline, lysine, hydroxyproline, the corresponding L or D enantiomers thereof or a derivative thereof. Preferably, the first amino acid is arginine or lysine and most preferably the first amino acid is arginine. The second amino acid is positioned at the carboxy end of the first amino acid. Suitable second amino acids comprise proline, glycine, serine, threonine, leucine, isoleucine, valine, alanine, hydroxyproline the corresponding L or D enantiomers thereof or a derivative thereof. Preferably, the second amino acid is proline or glycine and most preferably the second amino acid is proline.

A suitable positively charged group comprises a synthetic or naturally occurring amino acid. Preferably, the positively charged group is a primary amino group, secondary amino group, tertiary amino group, quaternary amino group, guanidinium group or amidinium group. It is preferred that the positively charged group is an amino acid bearing a net charge of at least +1. More preferably, the positively charged group is arginine, lysine, histidine or a derivative thereof. Most preferably, the positively charged group is arginine.

The positive patch may be joined to the polyamide using an "attachment" group. Preferably, the attachment group comprises an amino acid. More preferably, the attachment moiety is β -alanine, γ -aminobutyric acid, valeric acid, or any of the corresponding 2-amino derivatives of β -alanine, γ -aminobutyric acid, or valeric acid. Most preferably, the attachment group is β -alanine.

In addition, an improved polyamide of the present invention may further include a aliphatic amino acid such as β -alanine residue (β), an amide group such as dimethylaminopropylamide (Dp), an alcohol such as EtOH, an acid such as EDTA, or any derivative thereof may be joined to the β residue.



β -alanine may also be utilized in place of a pyrrole or hydroxypyrrole amino acid in Formulas I-VIII. The use of β -alanine in place of a pyrrole or hydroxypyrrole amino acid in the synthetic methods provides aromatic/aliphatic pairing (Im/ β , β /Im, Py/ β , and

β/Py) and aliphatic/aliphatic pairing (β/β) substitution. Such substitutions may comprise those described in provisional application 60/042,022, incorporated herein by reference. The use of γ -aminobutyric acid, or a substituted γ -aminobutyric acid such as (R)-2,4-diaminobutyric acid, provides for preferred hairpin turns. Inclusion of the positive patch
 5 allows the polyamide to deliver a positive residue to the DNA backbone and interfere with protein-phosphate contacts. As such, the positive patch contacts the major groove or the phosphate backbone of a DNA molecule and inhibits the binding or function of DNA-binding proteins. Many other groups suitable for the purposes of practicing this invention are well known and widely available to one skilled in the art.

10 The polyamide subunit structures I-VIII above may be covalently coupled through the γ residue which represents a $-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CONH}-$ hairpin linkage derived from γ -aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid. The present invention provides the reagents and methodologies for substituting the γ -residue of certain polyamides with a moiety such as (R)-2,4,-diaminobutyric acid
 15 ((R)^{H₂N} γ). The NMR structure of a hairpin polyamide of sequence composition ImPyPy- γ -PyPyPy complexed with a 5'-TGTTA-3' target site indicated that it was possible to substitute the α -position of the γ -aminobutyric acid residue within the hairpin-DNA complex (de Claire, et al. *J. Am. Chem. Soc.* 1997, 119, 7909). Modeling indicated that replacing the α -H of γ with an amino group that may confer an R-configuration at the
 20 α -carbon could be accommodated within the floor and walls of the minor groove as demonstrated in Figure 1 and 2A. In contrast, the (S)-2,4,-diaminobutyric acid ((S)^{H₂N} γ) linked hairpin is predicted to clash with the walls of the minor groove of the DNA helix as illustrated in Figures 1 and 2B.

In Formulas V-VIII, L represents an amino acid linking group such as β -alanine
 25 or 5-aminovaleric acid (δ) bound to the γ residue of a first polyamide and to the carboxytail of a second polyamide. As such, two or more polyamides may be linked, forming a tandemly-linked polyamide. Such a polyamide is said to be tandemly-linked or a tandem-linked polyamide.

P represents from zero to ten polyamides of formulas IX-XII:



that may be tandemly linked to another polyamide. Preferably, P represents from zero to eight polyamides of formulas IX-XII. More preferably, P represents from zero to six polyamides of formulas IX-XII. More preferably, P represents from zero to four polyamides of formulas IX-XII. Most preferably, P represents from zero to two polyamides of formulas IX-XII. In Formulas IX-XII, X_1 - X_{12} are as defined above. Tandem linking of polyamides provides expanded binding site size and increased binding affinity without compromising selectivity. Many other groups suitable for the purposes of practicing this invention are well known and widely available to one skilled in the art.

Baird, et al. (*J. Am. Chem. Soc.* 118: 6141-6146) and PCT/US97/003332 describe methods for synthesis of polyamides which are suitable for preparing polyamides of this invention. Polyamides of the present invention may be synthesized by solid phase methods using compounds such as Boc-protected 3-methoxypyrrole, imidazole, and pyrrole aromatic amino acids, which are cleaved from the support by aminolysis, deprotected with sodium thiophenoxide, and purified by reverse-phase HPLC. The identity and purity of the polyamides may be verified using any of a variety of analytical techniques available to one skilled in the art such as $^1\text{H-NMR}$, analytical HPLC, and/or matrix-assisted laser-desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS-monoisotropic).

Described herein is the synthesis of a new class of polyamides and their characterization with regard to DNA binding affinity and sequence specificity. Revealed herein to one skilled in the art are properties of positive patch elements that may be utilized as a guide in the design of more efficient polyamides. The present invention provides one skilled in the art with the reagents and methodologies for the design, synthesis and utilization of polyamides comprising a positive patch. As a representative example, a series of polyamides with Arg-Pro-Arg tripeptides at the C-terminus are provided. It is demonstrated that such polyamides selectively inhibit DNA binding by the

major groove-binding transcription factor GCN4, as measured by gel mobility shift assays. Polyamides having certain residues of the positive patch substituted are provided to identify the function of each amino acid in inhibition of protein binding. Also provided are DNase I footprint titration experiments to measure the effect of net ligand charge on both the DNA binding affinity and specificity of the hairpin polyamide. As demonstrated herein, addition of an Arg-Pro-Arg tripeptide does not result in significant alteration of polyamide-DNA binding affinity or specificity.

The instant invention provides polyamides that act as synthetic ligands to affect binding of proteins with affinity for the major groove of DNA, as well as methods of making and using such polyamides. In addition, sequences adjacent to or neighboring the protein binding site may be targeted, as exemplified by selective inhibition of GCN4 at two sites using Arg-Pro-Arg-polyamides. The Arg-Pro-Arg domain appears to adopt a stable and defined structure which delivers a neutralizing positive charge to the DNA backbone where it competes with GCN4 for contact to the phosphates. The broad targetable sequence repertoire of polyamides, coupled with the ubiquity of backbone contacts in protein recognition of DNA, make phosphate neutralization by a positive patch a promising approach for inhibition of major groove transcription factors.

One skilled in the art may utilize the examples provided herein to design polyamides comprising a positive patch sequence. The examples listed above and those illustrated below represent only certain embodiments of the present invention and are not limiting of the specification and claims in any way.

EXAMPLES

Example 1

Materials and Methods

All buffers for gel mobility shift and footprinting experiments were prepared from J.T. Baker reagents and 0.2 μ M filtered. EDTA and DTT were obtained from Gibco BRL. Poly(dI-dC)•poly(dI-dC) was from Pharmacia Biotech. Ficoll (MW 400,000) was purchased from Sigma. T4 polynucleotide kinase, *Eco*RI, *Pvu*II, and DNase I were from

Boehringer Mannheim. *Afl*II and *Fsp*I were purchased from New England Biolabs. Sequenase (version 2.0) was obtained from United States Biochemical. [α - 32 P]-Thymidine-5'-triphosphate (≥ 3000 Ci/mmol), [α - 32 P]-deoxyadenosine-5'-triphosphate (≥ 6000 Ci/mmol), and were purchased from Du Pont/NEN. [γ - 32 P]-Adenosine-5'-triphosphate (≥ 7000 Ci/mmol) was obtained from ICN. GCN4 (222-281) was prepared by solid phase synthesis. MBHA resin (0.57 mmol/g) was from Calbiochem. Boc- β -Ala, Boc- γ -aminobutyric acid, Boc-(Tos)Arg, Boc-Ala, Boc(CBz)Lys, Boc-Gly, Boc-Pro and Boc-D-Pro were from Peptides International. *p*-Cresol was purchased from Aldrich. All other chemicals, as well as the purification and characterization of polyamides were as previously described (Baird, et al. (1996) *J. Am. Chem. Soc.* 118, 6141-6146).

Example 2

Arg-Pro-Arg Polyamides

Schematic models of certain polyamides targeted to the binding site of the bZIP transcriptional activator GCN4 are illustrated in Figure 1, parts a-d. A series of polyamides with Arg-Pro-Arg tripeptides at the C-terminus were synthesized by solid phase methods. The polyamides were evaluated as inhibitors of the major groove transcription factor GCN4, the prototypical member of the basic region-leucine zipper (bZIP) family of transcriptional regulators (Hurst, H. C. (1995) *Protein Profile* 2, 105-168; Struhl, K. (1992) *Yeast GCN4 transcriptional activator protein*. In *Transcriptional Regulation*. (McKnight, S. L. & Yamamoto, K. R., eds), pp. 833-859, Cold Spring Harbor Laboratory Press, New York; Curran, T. & Vogt, P. (1992) *Dangerous liaisons: fos and jun, oncogenic transcription factors*. In *Transcriptional Regulation*. (McKnight, S. L. & Yamamoto, K. R., eds), pp. 797-832, Cold Spring Harbor Laboratory Press, New York). The C-terminal sixty amino acids (222-281) of GCN4 contain the "leucine zipper" dimerization domain and the "basic region" which is responsible for DNA binding. GCN4 (222-281) has been shown to be sufficient for sequence specific binding (Oakley, et al. (1990) *Science* 248, 847-850; Hope, et al. (1986) *Cell* 46, 885-894; Paolella et al. (1994) *Science* 264, 1130-1133). The basic region of each α -helical monomer makes specific hydrogen bonds, van der Waals contacts, and phosphate

interactions with one half-site of the nine base pair pseudosymmetrical GCN4 binding site (Figure 2 A & B) (Oakley, et al. (1990), supra; Ellenberger, et al. (1992) *Cell* 71, 1223-1237; König, et al. (1993) *J. Mol. Biol.* 233, 139-154). The protein-DNA electrostatic interactions which are targeted for disruption by the Arg-Pro-Arg-polyamides are highlighted in Figure 2B.

Homeodomain proteins recognize the minor groove of DNA via a highly conserved Arginine (Arg) - X_{aa} - Arg (X_{aa} = any amino acid) (Gehring, W. J., et al., & Wüthrich, K. (1994) Homeodomain-DNA recognition. *Cell* 78, 211-223; Gehring, et al. (1994) Homeodomain proteins. *Annu. Rev. Biochem.* 63, 487-526). In Hin recombinase, the corresponding Arg¹⁴⁰ - Proline¹⁴¹ (Pro) - Arg¹⁴² domain serves as a bridge between the N-terminal arm in the minor groove and the helix-turn-helix motif which recognizes the major groove (Sluka, et al. (1990) *Biochemistry* 29, 6551-6561; Feng, et al. (1994) *Science* 263, 348-355). Minor groove contacts made by the side chain of Arg¹⁴⁰ direct the peptide chain up from the floor of the minor groove, toward the backbone, where the guanidinium of Arg¹⁴² makes electrostatic contact with phosphates. Upon interaction with DNA, the Arg-Pro-Arg domain achieves a stable, local tertiary structure which is potentially based solely on the primary sequence. It was postulated that Arg-Pro-Arg attached at the C-terminus of a polyamide would adopt a similar structure to that of Arg¹⁴⁰-Pro¹⁴¹-Arg¹⁴² in Hin recombinase. The resulting Arg-Pro-Arg-polyamide could be used to place a neutralizing positive charge at a predetermined phosphate on the DNA backbone (Figure 3). Arg-Pro-Arg-polyamide synthesis is exemplified here for polyamide 3.

ImPyPyPy-γ-PyPyPyPy-β-RPR (compound 3)

Polyamides 1-4 are illustrated in Figure 4A-D. ImPyPyPy-γ-PyPyPyPy-β-RPR-MBHA-resin was synthesized in a stepwise fashion by machine-assisted solid phase methods [44] from MBHA resin (600 mg, 0.57 mmol/g, calculated as $L_{\text{new}}(\text{mmol/g}) = L_{\text{old}} / (1 + L_{\text{old}}(W_{\text{new}} - W_{\text{old}}) \times 10^{-3})$, where L is the loading (mmol of amine per gram of resin) and W is the weight (g mol⁻¹) of the growing peptide attached to the resin (Barlos, et al. (1991) *Int. J. Peptide Protein Res.* 37, 513-520). A sample of polyamide

resin (300 mg, 0.30 mmol/g) was placed in a Kel-F reaction vessel, *p*-cresol (1 g) added, and the vessel cooled to -60 °C. HF was then condensed into the vessel. The solution was stirred vigorously for one hour (0 °C) and the excess HF was removed *in vacuo*. The reaction mixture was then treated with cold ethyl ether (50 mL) and the resulting resin/polyamide coprecipitate was collected by vacuum filtration. The polyamide was then extracted with CH₃CN:H₂O:TFA (10:9:1), 0.1% (w/v) TFA added (6 mL) and the resulting solution purified by reverse phase HPLC using a Waters DeltaPak 25 × 100 mm 100 μm C₁₈ column in 0.1% (w/v) TFA, gradient elution 0.25%/min. CH₃CN. ImPyPyPy-γ-PyPyPyPy-β-RPR-NH₂ was recovered upon lyophilization of the appropriate fractions as a white powder (84 mg, 60% recovery); UV (H₂O) λ_{max} 244, 312 (66,000); ¹H NMR (DMSO-*d*₆): δ 10.49 (s, 1H), 9.96 (s, 1H), 9.93 (s, 1H), 9.90 (s, 3H), 9.84 (s, 1H), 8.19 (d, 1H, J=7.6 Hz), 8.07 (m, 1H), 8.02 (m, 1H), 7.95 (m, 1H), 7.91 (m, 1H), 7.53 (m, 3H), 7.38 (s, 1H), 7.26 (d, 1H, J=1.6 Hz), 7.25 (s, 1H), 7.21 (d, 1H, J=1.6 Hz), 7.20 (s, 1H), 7.19 (s, 1H), 7.14 (m, 3H), 7.03 (m, 4H), 6.87 (d, 1H, J=1.6 Hz), 6.85 (m, 2H), 4.48 (t, 1H, J=4.8 Hz), 4.27 (q, 1H, J=4.4 Hz), 4.77 (m, 1H), 3.96 (s, 3H), 3.81 (m, 12H), 3.80 (s, 3H), 3.77 (s, 3H), 3.76 (s, 3H), 3.60 (m, 2H), 3.32 (q, 2H, J=4.8 Hz), 3.17 (q, 2H, J=6.1 Hz), 3.0 (m, 4H), 2.36 (t, 2H, J=6.9 Hz), 2.25 (t, 2H, J=6.9 Hz), 2.0 (m, 2H), 1.77 (m, 4H), 1.64 (m, 2H), 1.46 (m, 6H).

The polyamides ImPyPyPy-γ-PyPyPyPy-β-Dp (1) and ImImPyPy-γ-ImPyPyPy-β-Dp (2) were synthesized in a stepwise manner from Boc-β-alanine-Pam resin using Boc-chemistry machine-assisted protocols as previously described (Baird, et al. (1996) *J. Am. Chem. Soc.* 118, 6141-6146). Polyamides with C-terminal aliphatic amino acids were synthesized on MBHA resin from Im and Py monomer units and commercially available aliphatic amino acids in 26 steps (Figures 4 and 5). Treatment with HF:*p*-cresol (9:1) followed by precipitation with ethyl ether and extraction with 0.1% TFA:CH₃CN (50:50) afforded the deprotected polyamide which was purified by reverse phase HPLC.

Example 3

Selective inhibition of GCN4 (222-281) binding by Arg-Pro-Arg polyamides

Synthetic DNA fragments were prepared on an ABI 380B Automated DNA Synthesizer and purified by preparative denaturing polyacrylamide gel electrophoresis.

5 ARE-1 (5'-CCGGATCCATGGTTGCTGACTAATTGTTATCCTCTAGAGTCGACC-3') and ARE-2 (5'-CCGGATCCATGGTTGCTGACTAATTGGTCTCCTCTAGAGTCGACC-3') were radiolabeled at the 5'-terminus with γ -³²P-ATP and T4 polynucleotide kinase, annealed to an equimolar amount of the unlabeled complement, and purified by nondenaturing polyacrylamide gel electrophoresis (Sambrook, et al. *Molecular Cloning*.
10 (2nd ed.). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY).

For gel mobility shifts, polyamide was incubated with radiolabeled synthetic DNA duplex (10 kcpm) in 40 μ L reaction volumes of bisTris (10 mM, pH 7.0), NaCl (100 mM), DTT (1 mM), EDTA (1 mM), and poly(dI-dC)•poly(dI-dC) (50 μ g/mL) for 16 hours at 22 °C (20 mM MOPS, pH 7.0, 140 mM KCl, 10 mM NaCl, 1mM MgCl₂, 1
15 mM spermine was used to model ionic conditions *in vivo*). GCN4 (222-281) was added and equilibrated for 30 minutes. Loading buffer (15% Ficoll, 0.025% bromophenol blue) (10 μ L) was added and 10 μ L was immediately loaded onto a running 8% (29:1, acrylamide:bis-acrylamide) polyacrylamide gel (0.5 X TBE, 280 V, 0.8 mm, 13 cm). Sufficient separation of the free DNA and the DNA•GCN4 (222-281) complexes was
20 achieved within 45 minutes. Gels were dried and exposed to a storage phosphor screen (Molecular Dynamics) (Johnston, et al. (1990) *Electrophoresis* 11, 355).

Synthetic radiolabeled DNA duplexes, ARE-1 and ARE-2, containing a GCN4 binding site (5'-CTGACTAAT-3') (Oakley, et al. (1990) *Science* 248, 847-85029; Oakley, et al. (1992) *Biochemistry* 31, 10969-10975), were bound near saturation at 200
25 nM GCN4 (222-281) as revealed by gel mobility shift analysis (10 mM bisTris pH 7.0, 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 50 μ g/mL poly(dI-dC)•poly(dI-dC), 22 °C). ImPyPyPy- γ -PyPyPyPy- β -polyamides (1 and 3) target the six base pair 5'-TGTTAT-3'

site adjacent to the GCN4 binding site of ARE-1 (Figure 6). ImImPyPy- γ -ImPyPyPy- β -polyamides (2 and 4) were designed to bind 5'-TGGTCT-3' adjacent to the GCN4 site in ARE-2 (Figure 6).

The ability of polyamides to inhibit GCN4 (222-281) binding was evaluated using the gel mobility shift assay. Increasing concentrations of polyamide were incubated with the desired radiolabeled synthetic DNA duplex followed by the addition of a constant concentration of 200 nM GCN4 (222-281). DNA fragments bound and unbound by GCN4 were separated using nondenaturing polyacrylamide gel electrophoresis.

Polyamides 1 and 2, which lack the Arg-Pro-Arg moiety were unable to inhibit GCN4 binding (Figure 6). The upper band in Figure 6A is the ARE-1 fragment bound by GCN4 (222-281) (lanes 2-12). Lanes 3-11 show that GCN4 binding was unaffected by the addition of ImPyPyPy- γ -PyPyPyPy- β -Dp. However, ImPyPyPy- γ -PyPyPyPy- β -RPR, which differs from 1 by the addition of the C-terminal Arg-Pro-Arg, inhibited GCN4 binding to ARE-1 (Figure 6C). When bound to its match site on ARE-2, ImImPyPy- γ -ImPyPyPy- β -RPR also successfully inhibited GCN4 binding (Figure 6F).

Based on the pairing rules for polyamide-DNA complexes, the sites 5'-TGTTAT-3' (ARE-1 fragment) and 5'-TGGTCT-3' (ARE-2 fragment) are for ImPyPyPy- γ -PyPyPyPy-RPR "match" and "double-base-pair mismatch" sites, respectively, and for ImImPyPy- γ -ImPyPyPy-RPR "double-base pair mismatch" and "match" sites, respectively. Incubation of GCN4 and up to 2 μ M ImPyPyPy- γ -PyPyPyPy- β -RPR with the double mismatch ARE-2 fragment resulted in no inhibition of GCN4 binding (Figure 6D). Likewise, ImImPyPy- γ -ImPyPyPy- β -RPR did not inhibit GCN4 binding to the mismatched ARE-1 fragment (Figure 6E).

When bound to their respective match sites, ImPyPyPy- γ -PyPyPyPy- β -RPRRRR (5) and ImImPyPy- γ -ImPyPyPy- β -RPRRRR (6), which contain an additional three C-terminal arginine residues relative to 3 and 4, were found to fully inhibit GCN4 (222-281) binding (Figures 7 and 8). The gel mobility shift experiments depicted in Figure 6

demonstrate that **5** and **6** selectively provided complete inhibition of GCN4 binding with no apparent loss in specificity for double-base-pair mismatches.

Example 4

5

Design of Optimum Tripeptide for GCN4 Inhibition

Polyamides with deletions and/or substitutions in the Arg-Pro-Arg domain were prepared in order to determine the elements which were essential for GCN4 inhibition (Figure 9). Each of these polyamides was based on the ImPyPyPy- γ -PyPyPyPy- β polyamide targeted to 5'-TGTTAT-3' of ARE-1. The ability of polyamides **7-14** (Figures 9 and 10) to bind their DNA target sites and inhibit GCN4 binding to ARE-1 was evaluated using DNase I footprinting and gel mobility shift analysis.

DNase I footprinting of polyamides **1-14** was performed on restriction fragments containing the appropriate ARE-1 or ARE-2 sequences under conditions identical to those used for the gel mobility shift experiments. In every case, (except **11**, see below) the polyamide was found to specifically bind the target site with $K_a \sim 1 \times 10^7 \text{ M}^{-1}$ (Figure 11). Lower K_a values are observed for polyamides under the gel shift conditions due to the carrier DNA which artificially depresses polyamide binding constants. The polyamide concentrations required for GCN4 inhibition are within the expected range based on the K_a under gel shift conditions.

20

Deletion of the terminal Pro-Arg or Arg, as in ImPyPyPy- γ -PyPyPyPy- β -R, (**7**) and ImPyPyPy- γ -PyPyPyPy- β -RP (**8**), results in polyamides which are unable to inhibit GCN4 binding. Substituting the proline with glycine afforded ImPyPyPy- γ -PyPyPyPy- β -RGR (**9**), which did not effectively inhibit GCN4 (222-281). At 1 μM of **9**, < 50% of the GCN4 was inhibited. No inhibition of GCN4 binding was observed for ImPyPyPy- γ -PyPyPyPy- β -R^DPR (**10**) which contained a single inversion of stereochemistry relative to **3**.

25

The internal arginine was replaced with an alanine residue to provide ImPyPyPy- γ -PyPyPyPy- β -APR (11). 11 was unable to inhibit GCN4 binding under these conditions. This Arg to Ala substitution was the only alteration which was found to affect polyamide binding affinity. By DNase I footprinting, 11 binds the 5'-TGTTAT-3' target site with ten-fold lower affinity than 3 under conditions identical to those used for gel shift analysis. The conservative substitution of lysine for arginine in ImPyPyPy- γ -PyPyPyPy- β -KPR (12) also compromised the polyamide's ability to inhibit GCN4. At 1 μ M 12, < 50% of the bound GCN4 was inhibited, similar to 9. However, the identical substitution in the C-terminal position afforded ImPyPyPy- γ -PyPyPyPy- β -RPK (13), which inhibited GCN4 binding identically to the Arg-Pro-Arg polyamide 3. The amino acid linkage between the final Py amino acid and the initial arginine was also crucial for GCN4 inhibition. A polyamide in which the β -alanine linker was replaced with a 7-aminoheptanoic acid linker, ImPyPyPy- γ -PyPyPyPy-C7-RPR (14), was unable to inhibit GCN4 binding. Protein inhibition did not require prebinding of polyamide. Preincubation of ARE-1 with GCN4 followed by addition of 5 afforded inhibition identical to that of prebound polyamide.

By targeting an 8-ring Arg-Pro-Arg-polyamide adjacent to a GCN4 binding site, selective inhibition of DNA binding by a protein which exclusively contacts the major groove is achieved (Figures 4 and 6). The polyamide domain binds sequence specifically in the minor groove with double base pair mismatches preventing GCN4 inhibition.

The inability of truncated analogs 7 (R) or 8 (RP) to inhibit GCN4 binding indicates that the C-terminal arginine in 3 (RPR) is crucial for GCN4 inhibition. Based on the Hin recombinase model, this arginine is expected to make non-specific contacts to the DNA phosphate backbone. The ability of 13 (RPK) to inhibit GCN4 identically to 3 (RPR) supports this model. The neutralization of a portion of the backbone is the most likely mechanism by which Arg-Pro-Arg polyamides achieve GCN4 inhibition. Other models, such as steric blockage of the major groove or DNA distortion, cannot be ruled

out (Strauss, et al. (1994) *Science* 266, 1829-1834). Modeling suggests that Arg-Pro-Arg is insufficient to cross the DNA backbone and block the major groove. Determination of the exact mechanism of inhibition awaits high-resolution structure studies which are in progress.

5 The results of GCN4 inhibition experiments with polyamides 7-14 suggest that the Arg-Pro-Arg of 3 and 4 adopts a stable and well-defined structure similar to Arg¹⁴⁰-Pro¹⁴¹-Arg¹⁴² of Hin recombinase. The internal Arg-Pro of 3 and 4 (RPR) is required for GCN4 inhibition. Polyamide 8 does not inhibit GCN4, suggesting that these two residues play a structural role in the placement of the terminal arginine near the phosphate backbone. Replacing the rigid proline of 3 (RPR) with a flexible glycine (9) (RGR) allows significant amounts of GCN4 to remain bound in the presence of saturating concentrations of 9. The glycine in 9 may permit the C-terminal arginine to shift to a position which permits simultaneous binding with GCN4.

10 ImPyPyPy-γ-PyPyPyPy-β-R^DPR (10) is a diastereomer of ImPyPyPy-γ-PyPyPyPy-β-RPR (3), but is unable to inhibit GCN4. Modeling indicates that substitution of D-proline for L-proline may in fact direct the neutralizing terminal arginine to the backbone of the opposite DNA strand. However, confirmation of this prediction awaits studies with other protein systems.

15 Replacement of the internal arginine with alanine, as in 11, reduces binding affinity by a factor of ten and prevents GCN4 inhibition. Furthermore, the Lys-Pro-Arg polyamide, 12, exhibits a binding affinity comparable to 3, yet it is a less effective inhibitor of GCN4. Together, these results suggest that the guanidinium of the internal arginine makes specific contacts with the DNA which are required for the proper positioning of the remaining residues. Replacement of the β-alanine linker (3) with 7-aminoheptanoic acid (14) eliminates inhibition, further implicating the placement of the Arg-Pro-Arg moiety as a requirement for effective inhibition.

20

25

Example 5

Salt Dependence of Positive Patch Polyamides

In order to evaluate the sensitivity of positive patch mediated major groove protein inhibition to the nature of the compensating electrolyte, as well as the overall ionic strength, gel mobility shift analysis was performed using a buffer which models the environment of the cellular nucleus (20 mM MOPS, pH 7.2, 140 mM KCl, 10 mM NaCl, 1 mM MgCl₂, 1 mM spermine) (Jones, et al. (1993) *J. Org. Chem.* 58, 2983-2991). Arg-Pro-Arg-polyamide 3 was found to inhibit GCN4 (222-281) binding under the *in vivo* ionic conditions which feature KCl as the primary compensating electrolyte and the conditions optimized for protein binding which feature NaCl as the predominant compensating electrolyte (Figure 6C). Further biophysical characterization of major groove protein inhibition by positive patch polyamides will be reported in due course.

Example 6

Arg-Pro-Arg Polyamide Binding Affinity and Specificity

In order to evaluate the effects of the Arg-Pro-Arg moiety on the DNA binding properties of the polyamides, quantitative DNase I footprint titration experiments were performed to determine the equilibrium association constants of polyamides 1-6 for their respective six base pair match and single-base-pair mismatch sites (10 mM Tris pH 7.0, 10 mM KCl, 10 mM MgCl₂, 5 mM CaCl₂, 22 °C) (Brenowitz, et al. (1986) *Methods Enzymol.* 130, 132-181).

The *Afl* II/*Fsp* I restriction fragment of pJT8 (Trauger, et al. (1996) *Nature* 382, 559-561) was 3'-³²P-end-labeled by digesting the plasmid with *Afl*II and *Fsp*I and simultaneously filling in using Sequenase, [α-³²P]-deoxyadenosine-5'-triphosphate, and [α-³²P]-thymidine-5'-triphosphate, and isolating the 229 bp fragment by nondenaturing gel electrophoresis. The 250 bp *Eco*RI/*Pvu*II restriction fragment of pJK6 (Struhl, K.

(1992) Yeast GCN4 transcriptional activator protein. In *Transcriptional Regulation*. (McKnight, S. L. & Yamamoto, K. R., eds), pp. 833-859, Cold Spring Harbor Laboratory Press, New York) was prepared in an analogous manner. A and G sequencing were carried out as described (Maxam, et al. (1980) *Methods Enzymol.* 65, 499-560; Iverson, et al. (1987). *Methods Enzymol.* 15, 7823-7830).

All reactions were executed in a total volume of 400 μ L. A polyamide stock solution or H₂O (for reference lanes) was added to an assay buffer containing radiolabeled restriction fragment (20 kcpm), affording final solution conditions of 10 mM Tris•HCl (pH 7.0), 10 mM KCl, 10 mM MgCl₂, 5 mM CaCl₂, and either (i) 0.001 nM-100 nM polyamide or (ii) no polyamide (for reference lanes). The solutions were allowed to equilibrate at 22 °C for 18h. Footprinting reactions were initiated by the addition of 4 μ L of a DNase I stock solution (at the appropriate concentration to give ~ 55% intact DNA) containing 1 mM dithiothreitol and allowed to proceed for seven min at 22 °C. The reactions were stopped by the addition of 50 μ L of a solution containing 1.25 M NaCl, 100 mM EDTA, 0.2 mg/mL glycogen, and 28 μ M base-pair calf thymus DNA, and ethanol precipitated. Reactions were resuspended in 1X TBE/80% formamide loading buffer, denatured by heating at 85 °C for 10 min, and placed on ice. The reaction products were separated by electrophoresis on an 8% polyacrylamide gel (5% cross-link, 7 M urea) in 1X TBE at 2000 V for 1.5h. Gels were dried and exposed to a storage phosphor screen (Molecular Dynamics) (Johnston, et al. (1990) *Electrophoresis* 11, 355).

Data from the footprint titration gels were obtained using a Molecular Dynamics 400S PhosphorImager followed by quantitation using ImageQuant software (Molecular Dynamics). Background-corrected volume integration of rectangles encompassing the footprint sites and a reference site at which DNase I reactivity was invariant across the titration generated values for the site intensities (I_{site}) and the reference intensity (I_{ref}). The apparent fractional occupancy (θ_{app}) of the sites were calculated using the equation:

$$\theta_{app} = 1 - \frac{I_{site} / I_{ref}}{I_{site}^0 / I_{ref}^0} \quad (1)$$

where I_{site}^0 and I_{ref}^0 are the site and reference intensities, respectively, from a control lane to which no polyamide was added. The $([L]_{tot}, \theta_{app})$ data points were fit to a Langmuir binding isotherm (eq 2, $n=1$) by minimizing the difference between θ_{app} and θ_{fit} , using the modified Hill equation:

$$\theta_{fit} = \theta_{min} + (\theta_{max} - \theta_{min}) \frac{K_a^n [L]^{n_{tot}}}{1 + K_a^n [L]^{n_{tot}}} \quad (2)$$

where $[L]_{tot}$ is the total polyamide concentration, K_a is the equilibrium association constant, and θ_{min} and θ_{max} are the experimentally determined site saturation values when the site is unoccupied or saturated, respectively. The data were fit using a nonlinear least-squares fitting procedure with K_a , θ_{max} , and θ_{min} as the adjustable parameters. All acceptable fits had a correlation coefficient of $R > 0.97$. At least three sets of data were used in determining each association constant. All lanes from each gel were used unless visual inspection revealed a data point to be obviously flawed relative to neighboring points.

DNase I footprinting of ImImPyPy- γ -ImPyPyPy- β -Dp (2), ImImPyPy- γ -ImPyPyPy- β -RPR (4), and ImImPyPy- γ -ImPyPyPy- β -RPRRRR (6) was performed on the 250 bp *EcoRI/PvuII* restriction fragment of pJK6 (Kelly, et al. (1993) *Proc. Natl. Acad. Sci., USA* 93, 6981-6985). 2 bound the match sites, 5'-TGGTCA-3' and 5'-TGGACA-3', with identical affinities within experimental error ($K_a = 1.3 (\pm 0.1) \times 10^{10} M^{-1}$ and $6.4 (\pm 1.2) \times 10^9 M^{-1}$, respectively). 2 also demonstrated greater than 100-fold specificity for a single base pair mismatch site 5'-TGTACA-3' ($K_a \leq 5 \times 10^7 M^{-1}$, mismatched base pair underlined). Similar affinity and a slight increase in specificity were observed for Arg-Pro-Arg polyamide 3. 5'-TGGTCA-3' and 5'-TGGACA-3' were bound by 3 ($K_a = 4.6 (\pm 0.2) \times 10^{10} M^{-1}$ and $6.6 (\pm 1.0) \times 10^{10} M^{-1}$, respectively) with greater than 450-fold specificity versus the mismatch site ($K_a \leq 1 \times 10^7 M^{-1}$). The additional three terminal arginines of 6 generated a ten-fold increase in affinity relative to

2 coupled with a significant loss in specificity for a single-base-pair mismatch. **6** bound 5'-TGGTCA-3', 5'-TGGACA-3', and 5'-TGTACA-3' with affinities of $2.6 (\pm 0.4) \times 10^{10} \text{ M}^{-1}$, $2.8 (\pm 0.5) \times 10^{10} \text{ M}^{-1}$ and $1.9 (\pm 0.8) \times 10^{10} \text{ M}^{-1}$, respectively.

Corresponding results were observed for DNase I footprinting of ImPyPyPy- γ -PyPyPyPy- β -Dp (**1**), ImPyPyPy- γ -PyPyPyPy- β -RPR (**3**) and ImPyPyPy- γ -PyPyPyPy- β -RPRRRR (**5**) on the 229 bp *AflIII*/*FspI* restriction fragment of pJT8 (Trauger, et al. (1996) *Nature* 382, 559-561). **1** has been shown to bind its six base pair match site, 5'-AGTTAT-3', with an affinity of $3.5 (\pm 0.8) \times 10^9 \text{ M}^{-1}$ and 7-fold specificity versus a single base pair mismatch site 5'-AGTACT-3' ($K_a = 5.0 (\pm 0.5) \times 10^8 \text{ M}^{-1}$, Table 3) (Trauger, et al. (1996) *Nature* 382, 559-561).

Table 3
Equilibrium Association Constants (M^{-1})

Polyamide	5'-AGTATT-3'	5'-AGTACT-3'
ImPyPyPy- γ -PyPyPyPy- β -Dp	3.5×10^9 *	5.0×10^8 *
ImPyPyPy- γ -PyPyPyPy- β -RPR	5.5×10^8	9.2×10^7
ImPyPyPy- γ -PyPyPyPy- β -RPRRRR	1.0×10^{10}	3.4×10^9

*Values reported for the six-base pair match (5'-AGTATT-3') and mismatch (5'-AGTACT-3') (mismatch underlined) sites are the mean values obtained from three DNase I footprint titration experiments on the *AflIII* / *FspI* restriction fragment of pJT8. The assays were carried out at 22°C at pH 7.0 in the presence of 10 mM Tris•HCl, 10 mM KCl, 10 mM MgCl₂, and 5 mM CaCl₂. *From Trauger, et al. (1996) *Nature* 382, 559-561.

The Arg-Pro-Arg polyamide **3** demonstrated only a slight loss in affinity and a similar specificity ($K_a = 5.5 (\pm 1.5) \times 10^8 \text{ M}^{-1}$ for 5'-AGTATT-3' and $9.2 (\pm 0.4) \times 10^7 \text{ M}^{-1}$ for 5'-AGTACT-3'). Analogous to **6**, the additional terminal arginines of **5** provided a ten-fold increase in affinity for the match site ($K_a = 1.0 (\pm 0.2) \times 10^{10} \text{ M}^{-1}$) and a severe loss in specificity for a single-base-pair mismatch ($K_a = 3.4 (\pm 0.5) \times 10^9 \text{ M}^{-1}$).

Quantitative DNase I footprinting demonstrates that the addition of a C-terminal Arg-Pro-Arg tripeptide as in **3** and **4** does not alter the DNA binding properties of eight-

ring hairpin polyamides (1 and 2). However, Arg-Pro-Arg-Arg-Arg-Arg-polyamides, 5 and 6, have increased binding affinity but no specificity for a single base pair mismatch site. DNase I footprinting and gel mobility shift analysis demonstrate that 5 and 6 retain their specificity versus double base pair mismatch sites. These results indicate that synthetic ligands may balance the benefits of additional charge with the consequence of lowered sequence specificity (Breslauer, et al. (1988) The origins of the DNA binding affinity and specificity of minor groove-directed ligands: correlations of thermodynamic and structural data. In *Structure and Expression (Vol. 2), DNA and Its Drug Complexes* (Sarma, R. H. & Sarma, M. H. eds), pp. 273-289, Academic Press). For example, a distamycin analog modified with a decaaza decabutylamine moiety on a pyrrole nitrogen interferes with binding of a major groove transcription factor (Bruice, et al. (1997) *Bioorg. Med. Chem.* 5, 685-692). Unfortunately, the sequence specificity of this molecule which contains potentially eleven positive charges has not been reported. The results described here suggest that such a molecule may bind DNA with reduced sequence specificity.

EXAMPLE 7

Inhibition of DNA-Binding Proteins by Polyamides

Oligonucleotides were synthesized and purified as previously described (Liberles, et al. (1996) *Proc. Natl. Acad. Sci., USA* 93, 9510-4). Polyamides were also synthesized as previously described and by Baird, et al. (1996, *J. Am. Chem. Soc.* 118, 6141-6). Briefly, synthesis was performed in a stepwise manner from Boc- β -Alanine-Pam resin. Polyamides were then cleaved by reaction with ((dimethylamino)propyl)-amine and purified by HPLC chromatography.

To prepare labeled DNA, plasmid DNA was digested with *Hind*III and *Eco*RI for gel shift analysis, or *Pvu*II and *Eco*RI for footprinting analysis, and simultaneously labeled with Sequenase 2.0, deoxyadenosine 5'-(α - 32 P)-triphosphate, thymidine 5'-(α - 32 P)-

triphosphate, and nonradioactive deoxynucleoside triphosphates. The fragment was purified by gel electrophoresis, treated with proteinase K, filtered, further extracted with phenol/chloroform, and precipitated with ethanol.

For DNase I and MPE footprint reactions, all reactions were equilibrated at 22°C, pH 5.5, in the presence of 45 mM MES, 1 mM MgCl₂, and labeled DNA for at least 24 hours. Footprinting reactions were carried out as previously described (Hertzberg, et al. (1984) *Biochemistry* 23, 3934-3945; Brenowitz, et al. (1986) *Proc. Natl. Acad. Sci., USA* 83, 8462-8466.).

To perform gel shift assays and titrations, all samples were equilibrated as above for at least 24 hours. One-tenth volume of 15% glycerol loading buffer was added and samples were run on a 10% polyacrylamide gel at 40°C, pH 5.5, with a 75:1 acrylamide/bis-acrylamide ratio in 45 mM Mes and 1 mM MgCl₂ with buffer recirculation. Quantitation of isotherms was performed by plotting the ligand concentration against the portion of labeled DNA in the bent conformation and curve fit using a Langmuir binding isotherm, as previously described (Brenowitz, et al. (1986) *Proc. Natl. Acad. Sci., USA* 83, 8462-8466; Bailly, et al. (1995) *J. Molecular Biology* 253, 1-7).

Two 15 bp purine tracts separated by one turn of the DNA helix (10 bp) were targeted by oligonucleotides containing two pyrimidine tracts (T and 'C) connected by a central T linker of size 2-9. It has been previously shown that such oligonucleotides bend DNA to a varying degree dependent upon the size of the linker (Liberles, D. A. & Dervan, P. B. (1996) *Proc. Natl. Acad. Sci., USA* 93, 9510-4). The intervening 10 bp not targeted by the third strand oligonucleotide can be bound by a polyamide specifically designed for that sequence, as depicted in Figures 13 and 14. The binding affinity of the polyamide for its target sequence has previously been determined under similar conditions and reported to be $3.7 \times 10^{10} \text{ M}^{-1}$ for PA1 and $5.0 \times 10^8 \text{ M}^{-1}$ for PA2, both much stronger than the affinity of either the unlinked 15mers for their sites, or the linked

bidentate oligonucleotides (Liberles, D. A. & Dervan, P. B. (1996) *Proc. Natl. Acad. Sci., USA* 93, 9510-4); Liberles, D. A. & Dervan, P. B. , unpublished data; Trauger, J. W., Baird, E. E. & Dervan, P. B. (1996) *Nature* 382, 559-61). Given the ability of polyamides to straighten DNA, it is demonstrated herein that targeting a polyamide to the
 5 intervening duplex of bent DNA can straighten it, displacing a ligand bound several base pairs distally, as depicted in Figure 15.

PA1 at a concentration of 100 pM can displace a DNA bending third strand oligonucleotide at a concentration of 1 μ M. This effect is clearly seen in Figure 16 for oligonucleotides with linkers of 2 and 3 T residues, bending DNA greater than 600. In
 10 these lanes, the more retarded bent structure is shifted to a less retarded structure with mobility similar to a double Y structure, where two oligonucleotides are bound by a single target DNA molecule with the polyamide presumably bound between them. For oligonucleotides with smaller bend angles, the polyamide does not displace the third strand oligonucleotide and the DNA distortion is probably not sufficient to preclude
 15 efficient polyamide binding. The specificity of this effect is seen in Figures 17A and 17B, where only PA1, but not PA2 can displace oligonucleotide 2 at a concentration of 100 pM, while neither can displace oligonucleotide 9.

These experiments were performed with simultaneous addition of polyamide and oligonucleotide. Next, we sought to determine if the order of addition was important
 20 given the reported half life of a bound third strand oligonucleotide on DNA at approximately 12 hours under near physiological conditions (Maher, et al. (1990) *Biochemistry* 29, 8820-8826). As shown in Figure 18, simultaneous addition, preincubation with polyamide for one hour, or preincubation with third strand oligonucleotide for 1 hour made little difference in the ability of the polyamide to inhibit
 25 binding of the third strand oligonucleotide, where 1 hour is less than expected association rate for both oligonucleotide and polyamide (Maher, L. J., Dervan, P. B. & Wold, B. J. (I

990) Biochemistry 29, 8820-8826; Albert, et al. (1997), submitted). As such, polyamides may be useful in targeting prebound transcription factors in cells.

It has been shown that the energy required to bend DNA with bidentate triple helical ligands is less than predicted by theoretical models of DNA as a smoothly bending wormlike chain with coulombic repulsion from phosphates placed at fixed distances (Akiyama, T. & Hogan, M. E. (1996) J. Biological Chemistry 271, 29126-29135; Liberles, D. A. & Dervan, P. B., unpublished data; Bloomfield, et al. (1974) in Physical Chemistry of Nucleic Acids (Harper and Row, New York), pp. 159-166; Fenley, et al. (1992) J Physical Chemistry 96, 3963-3969). However, the prebending of target DNA for TBP, a general transcription factor, significantly altered its binding affinity (Parvin, et al. (1995) Nature 373, 724-727). The effects of prebending on the affinity of the polyamide by measuring the K_a , against triplex mediated bending was determined. Figure 17 shows a sample gel shift titration, where the measured K_a , for PA1 is $6.2 (\pm 0.3) \times 10^{10}$, whereas K_a , for PA2 is $<1 \times 10^9 \text{ M}^{-1}$. K_a , for PA1 is within experimental error of K_a measured by DNase I footprinting and shows that the energy for straightening DNA bent by a ligand with a lower binding affinity is minimal (Trauger, et al. (1996) Nature 382, 559-61). Bending effects with TBP may be much larger, given the large number of protein-DNA contacts supporting the bent structure (Kim, et al. (1993) Nature 365, 512-520; Bond, et al. (1994) Biophysical Journal 67, 825-836). Additionally, TBP-bound DNA is bent towards the major groove, not the minor groove.

To confirm that binding of the polyamide is indeed in the intervening duplex, DNase I and MPE footprinting were performed, as shown in Figure 17. While no binding in the intervening duplex and no displacement of the third strand oligonucleotide are seen for PA2, PA1 dislodges the third strand oligonucleotide, while protecting the intervening duplex. This supports the model of displacement of the bending ligand.

The mechanism of action of polyamides is assumed to be directly through rigidification of the double helix. Alternative modes of action to be considered are

simple steric blockage, or disruption of the solvation shell or counterion shell. Modeling of the triple helix-mediated bend shows a linker that is displaced from the intervening duplex to accommodate the bend angle, where shorter linkers are displaced further from the duplex than longer linkers. The inability of PA1 to displace bending oligonucleotides with longer linkers and bend angles less than 600 degrees argues against this explanation. Disruption of the solvation shell in the minor groove is likely to be steric and therefore unlikely to extend into the triple helical region where no polyamide is bound. Furthermore, this minor groove effect is unlikely to effect binding of a third strand in the major groove, where simultaneous binding has previously been demonstrated (Parks, et al. (1996) Bioorganic & Medicinal Chemistry 4, 1045-50). Similarly, the high charge density of double helical and triple helical DNA results in a large counterion shell around the molecule and in a very short Debye screening length where charge effects are unlikely to extend for multiple base pairs (Bond, et al. (1994) Biophysical Journal 67, 825-836; Philpott, et al. (1995) J. Electrochem. Soc. 142, L25-L28.).

By modifying DNA structure, generalizable sequence-specific polyamides have been designed to displace a DNA bending ligand at an adjacent but nonoverlapping binding site. This ability to displace DNA bending ligands through rigidification may be useful in the design of polyamides as artificial regulators of gene expression, providing a potentially valuable tool in molecular biology and human medicine.

As disclosed herein, the present invention provides the reagents and methodologies for the preparation and use of a variety of new polyamides comprising positive patch sequences for specific recognition of DNA in the minor groove and inhibiting the function of DNA-binding proteins that bind the major groove. Also provided is a methodology for determining the mechanism of action of inhibition of DNA-binding molecules. While a preferred form of the invention has been shown in the drawings and described, since variations in the preferred form will be apparent to those

skilled in the art, the invention should not be construed as limited to the specific form shown and described, but instead is as set forth in the claims.

CLAIMS

We claim:

1. In a polyamide which specifically binds to base pairs in the minor groove of a DNA molecule, the improvement comprising a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or the major groove of a DNA molecule.
2. A polyamide of claim 1 wherein the rigid group comprises a first and a second amino acid; said first amino acid being selected from the group consisting of arginine, proline, lysine, hydroxyproline and a derivative thereof; and said second amino acid being selected from the group consisting of proline, glycine, serine, threonine, leucine, isoleucine, valine, alanine, hydroxyproline and a derivative thereof.
3. A polyamide of claim 2 wherein said first amino acid is arginine and said second amino acid is proline.
4. A polyamide of claim 1 wherein the positively charged group comprises a synthetic or naturally occurring amino acid having a net positive charge.
5. A polyamide of claim 1 wherein said positively charged group is selected from the group consisting of a primary amino group, secondary amino group, tertiary amino group, quaternary amino group, guanidinium group, and an amidinium group.
6. A polyamide of claim 1 wherein said positively charged group is selected from the group consisting of arginine, lysine, histidine and a derivative thereof.
7. A polyamide of claim 1 wherein said positively charged group is arginine.


8. A polyamide of claim 1 wherein the positive patch comprises the amino acid sequence Arg-Pro-Arg.

9. A polyamide of claim 1 wherein the polyamide has three or four carboxamide binding pairs.

10. A polyamide of claim 1 wherein the polyamide comprises an (R)-2,4-diaminobutyric acid hairpin turn that facilitates specific binding to base pairs in the minor groove of a DNA molecule.

11. A polyamide of claim 10 wherein the R-2-amino group is derivatized to form an acid amide.

12. A polyamide of claim 1 having the formula:




wherein γ is $-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CONH}-$ hairpin linkage derived from γ -aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid;

X_1/X_6 , X_2/X_5 , and X_3/X_4 represent three carboxamide binding pairs which bind DNA base pairs and are selected from the group consisting of Hp/Py, Py/Hp, Py/Im, Im/Py, and Py/Py to correspond to the DNA base pair in the minor groove to be bound; and

A represents a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or major groove of a DNA molecule.

13. A polyamide of claim 12 wherein the positive patch comprises the amino acid sequence Arg-Pro-Arg.

14. A polyamide of claim 1 having the formula:




wherein γ is $-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CONH}-$ hairpin linkage derived from γ -aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid;

X_1/X_8 , X_2/X_7 , X_3/X_6 , and X_4/X_5 represent four carboxamide binding pairs which bind DNA base pairs and are selected from the group consisting of Hp/Py, Py/Hp, Py/Im, Im/Py, and Py/Py to correspond to the DNA base pair in the minor groove to be bound; and

A represents a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or major groove of a DNA molecule.

15. A polyamide of claim 14 wherein the positive patch comprises the amino acid sequence Arg-Pro-Arg.

16. A polyamide of claim 1 having the formula:




wherein γ is $-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CONH}-$ hairpin linkage derived from γ -aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid;

X_1/X_{10} , X_2/X_9 , X_3/X_8 , X_4/X_7 , X_5/X_6 represent five carboxamide binding pairs which bind DNA base pairs and are selected from the group consisting of Hp/Py, Py/Hp, Py/Im, Im/Py, and Py/Py to correspond to the DNA base pair in the minor groove to be bound; and

A represents a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or major groove of a DNA molecule.

17. A polyamide of claim 16 wherein the positive patch comprises the amino acid sequence Arg-Pro-Arg.

- 5 18. A polyamide of claim 1 having the formula:




wherein γ is -NH-CH₂-CH₂-CH₂-CONH- hairpin linkage derived from γ -aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid;

- 10 X_1/X_{12} , X_2/X_{11} , X_3/X_{10} , X_4/X_9 , X_5/X_8 , X_6/X_7 represent three or four carboxamide binding pairs which bind DNA base pairs and are selected from the group consisting of Hp/Py, Py/Hp, Py/Im, Im/Py, and Py/Py to correspond to the DNA base pair in the minor groove to be bound; and

- 15 A represents a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or major groove of a DNA molecule.

19. A polyamide of claim 18 wherein the positive patch comprises the amino acid sequence Arg-Pro-Arg.

- 20 20. A tandem-linked polyamide having the formula:



25 wherein γ is -NH-CH₂-CH₂-CH₂-CONH- hairpin linkage derived from γ -aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid;

X_1/X_6 , X_2/X_5 , X_3/X_4 , X'_1/X'_6 , X'_2/X'_5 , X'_3/X'_4 represent carboxamide binding pairs which bind DNA base pairs selected from the group consisting of Hp/Py, Py/Hp,

Py/Im, Im/Py, and Py/Py to correspond to the DNA base pair in the minor groove to be bound;


L represents an amino acid linking group selected from the group consisting of β -alanine and 5-aminovaleric acid (δ);

P represents a polyamide selected from the group consisting of

$X_1X_2X_3\gamma X_4X_5X_6$, $X_1X_2X_3X_4\gamma X_5X_6X_7X_8$, $X_1X_2X_3X_4X_5\gamma X_6X_7X_8X_9X_{10}$, and $X_1X_2X_3X_4X_5X_6\gamma X_7X_8X_9X_{10}X_{11}X_{12}$ where X_1 - X_{12} are independently selected from the group consisting of β -alanine, pyrrole, hydroxypyrrole and imidazole; and

A represents a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or major groove of a DNA molecule.

21. A tandem-linked polyamide having the formula:



wherein γ is -NH-CH₂-CH₂-CH₂-CONH- hairpin linkage derived from γ -

aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid;

X_1/X_8 , X_2/X_7 , X_3/X_6 , X_4/X_5 , X'_1/X'_8 , X'_2/X'_7 , X'_3/X'_6 , and X'_4/X'_5 represent carboxamide binding pairs which bind DNA base pairs selected from the group consisting of Hp/Py, Py/Hp, Py/Im, Im/Py, and Py/Py to correspond to the DNA base pair in the minor groove to be bound;


L represents an amino acid linking group selected from the group consisting of β -alanine and 5-aminovaleric acid (δ);

P represents a polyamide selected from the group consisting of

$X_1X_2X_3\gamma X_4X_5X_6$, $X_1X_2X_3X_4\gamma X_5X_6X_7X_8$, $X_1X_2X_3X_4X_5\gamma X_6X_7X_8X_9X_{10}$, and $X_1X_2X_3X_4X_5X_6\gamma X_7X_8X_9X_{10}X_{11}X_{12}$ where X_1 - X_{12} are independently selected from the group consisting of β -alanine, pyrrole, hydroxypyrrole and imidazole; and

A represents a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or major groove of a DNA molecule.

- 5 22. A tandem-linked polyamide having the formula:



wherein γ is $-\text{NH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CONH}-$ hairpin linkage derived from γ -aminobutyric acid or a chiral hairpin linkage derived from R-2,4-diaminobutyric acid;

- 10 X_1/X_{10} , X_2/X_9 , X_3/X_8 , X_4/X_7 , X_5/X_6 , X'_1/X'_{10} , X'_2/X'_9 , X'_3/X'_8 , X'_4/X'_7 , X'_5/X'_6 represent carboxamide binding pairs which bind DNA base pairs selected from the group consisting of Hp/Py, Py/Hp, Py/Im, Im/Py, and Py/Py to correspond to the DNA base pair in the minor groove to be bound;

- 15 L represents an amino acid linking group selected from the group consisting of β -alanine, 5-aminovaleric acid (δ) and a derivative thereof;

P represents a polyamide selected from the group consisting of

$X_1X_2X_3\gamma X_4X_5X_6$, $X_1X_2X_3X_4\gamma X_5X_6X_7X_8$, $X_1X_2X_3X_4X_5\gamma X_6X_7X_8X_9X_{10}$, and $X_1X_2X_3X_4X_5X_6\gamma X_7X_8X_9X_{10}X_{11}X_{12}$ where X_1-X_{12} are independently selected from the group consisting of β -alanine, pyrrole, hydroxypyrrole and imidazole; and

- 20 A represents a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or major groove of a DNA molecule.

- 5



15

P represents a polyamide selected from the group consisting of

A represents a positive patch consisting of a rigid group adjacent to a positively charged group such that a positive charge is delivered to the phosphate backbone or major groove of a DNA molecule.

24. A polyamide of claim 1 selected the group consisting of:

ImPyPyPy- γ -PyPyPyPy- β -RPR;

ImImPyPy- γ -ImPyPyPy- β -RPR;

ImPyPyPy- γ -PyPyPyPy- β -RPRRRR;

ImImPyPy- γ -ImPyPyPy- β -RPRRRR;

ImPyPyPy- γ -PyPyPyPy- β -R;

ImPyPyPy- γ -PyPyPyPy- β -RP;

ImPyPyPy- γ -PyPyPyPy- β -RGR;

ImPyPyPy- γ -PyPyPyPy- β -R^DPR;

ImPyPyPy- γ -PyPyPyPy- β -APR;

ImPyPyPy- γ -PyPyPyPy- β -KPR;

ImPyPyPy- γ -PyPyPyPy- β -RPK;

ImPyPyPy- γ -PyPyPyPy- β -C7-RPR; and

the pharmaceutically acceptable salts thereof.

25. A method of inhibiting gene expression comprising contacting a regulatory sequence of a gene with a polyamide of claim 1.

26. A method of inhibiting gene expression comprising contacting a DNA molecule with a polyamide of claim 1 whereby the DNA molecule is conformationally constrained.

ABSTRACT

This invention provides improved polyamides comprising a positive patch for contacting the phosphate backbone or major groove of a DNA molecule. As such, the improved polyamides are capable of inhibiting the function or binding of a DNA-binding protein to a DNA molecule. The improved polyamide provides for more efficient function of the polyamide.







FIGURE 1




(1) ImPyPyPy-γ-PyPyPyPy-β-Dp



(2) ImImPyPy-γ-ImPyPyPy-β-Dp



(3) ImPyPyPy-γ-PyPyPyPy-β-RPR



(4) ImImPyPy-γ-ImPyPyPy-β-RPR

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5






FIGURE 6



(5) ImPyPyPy- γ -PyPyPyPy- β -RPRRRR



(6) ImImPyPy- γ -ImPyPyPy- β -RPRRRR

FIGURE 7






FIGURE 8



ImPyPyPy- γ -PyPyPyPy-X




Polyamide	X =	Inhibition	Polyamide	X =	Inhibition
1		β -Dp -	10		β -RDPR -
3		β -RPR ++	11		β -APR -
7		β -R -	12		β -KPR +
8		β -RP -	13		β -RPK ++
9		β -RGR +	14		C_7 -RPR -

FIGURE 9



(14) ImPyPyPy- γ -PyPyPyPy-C7-RPR

FIGURE 10



ImImPyPy-γ-ImPyPyPy-β-Dp

$K_d (M^{-1})$

I	5'-AATCATG GTCATA-3'		1.3×10^{10}
	3'-TTAGTACCA GTAT-5'		
II	5'-CTCATTT G GACAGC-3'		6.4×10^9
	3'-GAGTAA C C T G T C G-5'		
III	5'-CTCATTT G TACAGC-3'		$\leq 5 \times 10^7$
	3'-GAGTAA C A T G T C G-5'		

ImImPyPy-γ-ImPyPyPy-β-RPR

I	5'-AATCATG GTCATA-3'		4.6×10^9
	3'-TTAGTACCA GTAT-5'		
II	5'-CTCATTT G GACAGC-3'		6.6×10^9
	3'-GAGTAA C C T G T C G-5'		
III	5'-CTCATTT G TACAGC-3'		$\leq 1 \times 10^7$
	3'-GAGTAA C A T G T C G-5'		

ImImPyPy-γ-ImPyPyPy-β-RPRRRR

I	5'-AATCATG GTCATA-3'		2.6×10^{10}
	3'-TTAGTACCA GTAT-5'		
II	5'-CTCATTT G GACAGC-3'		2.8×10^{10}
	3'-GAGTAA C C T G T C G-5'		
III	5'-CTCATTT G TACAGC-3'		1.9×10^{10}
	3'-GAGTAA C A T G T C G-5'		

FIGURE 11






FIGURE 12

A-1



A-2



n=2-6,9

FIGURE 13

662122-10041222




FIGURE 14





FIGURE 15

$$\begin{array}{cccc} 2 & 2 & 3 & 3 \\ \cdot & + & \cdot & + \end{array}$$


oligonucleotide	-	-	-	2	2	2
polyamide	-	1	2	-	1	2



FIGURE 17A

662620-402420

oligonucleotide	-	-	-	9	9	9
polyamide	-	1	2	-	1	2



FIGURE 17B

662480-404800




FIGURE 18

**DECLARATION
AND POWER OF ATTORNEY
Utility Application**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **INHIBITION OF MAJOR GROOVE DNA BINDING PROTEINS BY MODIFIED POLYAMIDES**, the specification of which

(Check One)

☐
☒

is attached hereto OR
was filed on herewith, as United States Application Serial No.
to be assigned or PCT International Application No. PCT/US98/02684 and
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Date of Filing	Priority Claimed	
			Yes	No
97/03332	PCT	February 20, 1997	X	
97/12722	PCT	July 21, 1997	X	

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date
60/038,384	February 14, 1997
60/023,309	July 31, 1996
60/024,374	August 1, 1996
60/026,713	September 25, 1996

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date	Status-Patented, Pending or Abandoned
08/853,522		May 8, 1997	Pending
08/837,524		April 21, 1997	Pending
08/607,078		February 26, 1996	Pending

POWER OF ATTORNEY: As a named inventor, I hereby appoint as my attorneys and/or agents, with full power of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Roland N. Smoot, Reg. No. 18,718; Conrad R. Solum, Jr. Reg. No. 20,467; James W. Geriak, Reg. No. 20,233; Robert M. Taylor, Jr., Reg. No. 19,848; Samuel B. Stone, Reg. No. 19,297; Douglas E. Olson, Reg. No. 22,798; Robert E. Lyon, Reg. No. 24,171; Robert C. Weiss, Reg. No. 24,939; Richard E. Lyon, Jr., Reg. No. 26,300; John D. McConaghy, Reg. No. 26,773; William C. Steffin, Reg. No. 26,811; Coe A. Bloomberg, Reg. No. 26,605; J. Donald McCarthy, Reg. No. 25,119; John M. Benassi, Reg. No. 27,483; James H. Shalek, Reg. No. 29,749; Allan W. Jansen, Reg. No. 29,035; Robert W. Dickerson, Reg. No. 29,914; Roy L. Anderson, Reg. No. 30,240; David B. Murphy, Reg. No. 31,125; James C. Brooks, Reg. No. 29,898; Jeffrey M. Olson, Reg. No. 30,790; Steven D. Hemminger, Reg. No. 30,755; Jerrold B. Reilly, Reg. No. 32,293; Paul H. Meier, Reg. No. 32,274; John A. Rafter, Jr., Reg. No. 31,653; Kenneth H. Ohriner, Reg. No. 31,646; Mary S. Consalvi, Reg. No. 32,212; Lois M. Kwasigroch, Reg. No. 35,579; Lawrence R. LaPorte, Reg. No. 38,948; Robert C. Laurenson, Reg. No. 34,206; Bradford J. Duft, Reg. No. 32,219; Suzanne L. Biggs, Reg. No. 30,158; Richard J. Warburg, Reg. No. 32,327; John M. Johnson, Reg. No. 33,334; Daniel M. Chambers, Reg. No. 34,561; Troy M. Schmelzer, Reg. No. 36,667; Jessica R. Wolff, Reg. No. 37,261; Douglas C. Murdock, Reg. No. 37,549; Jeffrey W. Guise, Reg. No. 34,613; F.T. Alexandra Mahaney, Reg. No. 37,668; Charles S. Berkman, Reg. No. 38,077; Edward M. Jordan, Reg. No. 40,666; John C. Kappos, Reg. No. 37,861; Howard N. Wisnia, Reg. No. 37,502; Keith Kind, Reg. No. 42,735; Stephen S. Korniczky, Reg. No. 34,853; Jonathan T. Losk, Reg. No. 39,755; Theodore S. Maceiko, Reg. No. 35,593; Hope E. Melville, Reg. No. 34,874; Jeffrey A. Miller, Reg. No. 35,874; Kurt T. Mulville, Reg. No. 37,194; Clarke W. Neumann, Reg. No. 39,789; Vicki Norton, Reg. No. 40,745; Kenneth S. Roberts, Reg. No. 38,283; Thomas R. Rouse, Reg. No. 40,793; James K. Sakaguchi, Reg. No. 41,285; James K. Sakaguchi, Reg. No. 41,285; Carol A. Schneider, Reg. No. 34,923; Sheryl R. Silverstein, Reg. No. 40,812; Brent D. Sokol, Reg. No. 38,621; Jeffrey D. Tekanic, Reg. No. 36,031; Christopher A. Vanderlaan, Reg. No. 37,747; David E. Wang, Reg. No. 38,358; Lisa Ward Karmelich, Reg. No. 41,421; Michael J. Wise, Reg. No. 34,047; Wesley B. Ames, Reg. No. 40,893; Charles Balgenorth, Reg. No. 37,586; Thomas J. Brindisi, Reg. No. 40,348; James P. Brogan, Reg. No. 35,833; David T. Burse, Reg. No. 37,104; Bruce G. Chapman, Reg. No. 33,846; Farshad Farjami, Reg. No. 41,014; Charles C. Fowler, Reg. No. 39,675; and Corrine M. Freeman, Reg. No. 37,625.; of LYON & LYON, 633 West Fifth Street, Suite 4700, Los Angeles, California 90071-2066 telephone (619) 552-8400.

Send Correspondence to: Richard J. Warburg	LYON & LYON LLP 633 W Fifth St., Suite 4700 Los Angeles, CA 90071	Direct Telephone calls to: (619) 552-8400
---	---	--

	FULL NAME OF INVENTOR	FIRST Name Eldon	MIDDLE Initial E.	LAST Name Baird	
201	RESIDENCE & CITIZENSHIP	City Foster City	State or Foreign Country California	Country of Citizenship USA	
	POST OFFICE ADDRESS	311 Halyard Lane	City Foster City	State or Country California	Zip Code 94404
	FULL NAME OF INVENTOR	FIRST Name Peter	MIDDLE Initial B.	LAST Name Dervan	
202	RESIDENCE & CITIZENSHIP	City San Marino	State or Foreign Country California	Country of Citizenship USA	
	POST OFFICE ADDRESS	1235 St. Albans Road	City San Marino	State or Country California	Zip Code 91108
	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	
203	RESIDENCE & CITIZENSHIP	City	State or Foreign Country	Country of Citizenship	
	POST OFFICE ADDRESS		City	State or Country	Zip Code
	FULL NAME OF INVENTOR	FIRST Name	MIDDLE Initial	LAST Name	

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code §1001, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of Inventor	201
Date	8-6-99
Signature of Inventor	202
Date	
Signature of Inventor	203
Date	

Signature of Inventor	204
Date	8-6-99
Signature of Inventor	205
Date	
Signature of Inventor	206
Date	

(Signatures should conform to names as presented at 201 et seq. above.)